0000868278 2026-01-01 2026-03-31 0000868278 2026-06-29 0000868278 2026-03-31 0000868278 2025-12-31 0000868278 us-gaap:NonrelatedPartyMember 2026-03-31 0000868278 us-gaap:NonrelatedPartyMember 2025-12-31 0000868278 srt:AffiliatedEntityMember 2026-03-31 0000868278 srt:AffiliatedEntityMember 2025-12-31 0000868278 us-gaap:RelatedPartyMember 2026-03-31 0000868278 us-gaap:RelatedPartyMember 2025-12-31 0000868278 us-gaap:ConvertibleNotesPayableMember 2026-03-31 0000868278 us-gaap:ConvertibleNotesPayableMember 2025-12-31 0000868278 2025-01-01 2025-03-31 0000868278 us-gaap:CommonStockMember 2025-12-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0000868278 PRPH:SubscriptionReceivableMember 2025-12-31 0000868278 us-gaap:RetainedEarningsMember 2025-12-31 0000868278 us-gaap:TreasuryStockCommonMember 2025-12-31 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0000868278 us-gaap:CommonStockMember 2024-12-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000868278 PRPH:SubscriptionReceivableMember 2024-12-31 0000868278 us-gaap:RetainedEarningsMember 2024-12-31 0000868278 us-gaap:TreasuryStockCommonMember 2024-12-31 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000868278 2024-12-31 0000868278 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0000868278 PRPH:SubscriptionReceivableMember 2026-01-01 2026-03-31 0000868278 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0000868278 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-03-31 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0000868278 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000868278 PRPH:SubscriptionReceivableMember 2025-01-01 2025-03-31 0000868278 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000868278 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0000868278 us-gaap:CommonStockMember 2026-03-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0000868278 PRPH:SubscriptionReceivableMember 2026-03-31 0000868278 us-gaap:RetainedEarningsMember 2026-03-31 0000868278 us-gaap:TreasuryStockCommonMember 2026-03-31 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0000868278 us-gaap:CommonStockMember 2025-03-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000868278 PRPH:SubscriptionReceivableMember 2025-03-31 0000868278 us-gaap:RetainedEarningsMember 2025-03-31 0000868278 us-gaap:TreasuryStockCommonMember 2025-03-31 0000868278 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0000868278 2025-03-31 0000868278 2025-09-22 2025-09-22 0000868278 PRPH:StellaPurchaseAgreementMember 2023-01-03 2023-01-03 0000868278 2023-01-03 0000868278 2023-01-03 2023-01-03 0000868278 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-01-03 2023-01-03 0000868278 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-01-03 0000868278 us-gaap:TradeNamesMember 2026-03-31 0000868278 us-gaap:TradeNamesMember 2025-12-31 0000868278 us-gaap:IntellectualPropertyMember 2026-03-31 0000868278 us-gaap:IntellectualPropertyMember 2025-12-31 0000868278 us-gaap:CustomerRelationshipsMember 2026-03-31 0000868278 us-gaap:CustomerRelationshipsMember 2025-12-31 0000868278 PRPH:CLIALicenseMember 2026-03-31 0000868278 PRPH:CLIALicenseMember 2025-12-31 0000868278 PRPH:NoteMember us-gaap:ConvertibleNotesPayable 2026-01-13 0000868278 PRPH:NoteMember us-gaap:ConvertibleNotesPayable 2026-01-13 2026-01-13 0000868278 PRPH:JanuaryLabrysNoteMember us-gaap:ConvertibleNotesPayable 2026-01-27 0000868278 PRPH:JanuaryLabrysNoteMember us-gaap:ConvertibleNotesPayable 2026-01-27 2026-01-27 0000868278 PRPH:JanuaryLabrysNoteMember PRPH:JanuaryLabrysSPAMember us-gaap:ConvertibleNotesPayable 2026-01-27 0000868278 PRPH:MarchLabrysNoteMember us-gaap:ConvertibleNotesPayable 2026-03-10 0000868278 PRPH:MarchLabrysNoteMember us-gaap:ConvertibleNotesPayable 2026-03-10 2026-03-10 0000868278 PRPH:JanuaryLabrysNoteMember us-gaap:ConvertibleNotesPayable 2026-03-10 0000868278 PRPH:MarchLabrysNoteMember PRPH:MarchLabrysSPAMember us-gaap:ConvertibleNotesPayable 2026-03-10 0000868278 PRPH:ConvertibleNoteMember 2026-03-10 0000868278 PRPH:FirstTwentyTwentySixFutureReceiptsFinancingAgreementMember us-gaap:LoansPayable 2026-03-17 2026-03-17 0000868278 PRPH:FirstTwentyTwentySixFutureReceiptsFinancingAgreementMember us-gaap:LoansPayable 2026-03-17 0000868278 PRPH:FirstTwentyTwentySixFutureReceiptsFinancingAgreementMember us-gaap:LoansPayable 2026-03-31 0000868278 PRPH:SecondTwentyTwentySixFutureReceiptsFinancingAgreementMember us-gaap:LoansPayable 2026-03-17 2026-03-17 0000868278 PRPH:SecondTwentyTwentySixFutureReceiptsFinancingAgreementMember us-gaap:LoansPayable 2026-03-17 0000868278 PRPH:SecondTwentyTwentySixFutureReceiptsFinancingAgreementMember us-gaap:LoansPayable 2026-03-31 0000868278 PRPH:NonConvertiblePromissoryNotesMember 2025-06-22 0000868278 PRPH:NonConvertiblePromissoryNotesMember 2025-06-22 2025-06-22 0000868278 PRPH:CEOLoanMember 2025-06-22 0000868278 PRPH:CEOLoanMember 2025-06-22 2025-06-22 0000868278 PRPH:CEOWarrantsMember PRPH:CEOLoanMember 2025-06-22 0000868278 PRPH:CEOWarrantsMember PRPH:CEOLoanMember 2025-06-22 2025-06-22 0000868278 PRPH:A2024TermNoteMember 2025-06-22 2025-06-22 0000868278 PRPH:UnaffiliatedInvestorLoanMember 2025-06-22 0000868278 PRPH:UnaffiliatedInvestorWarrantsMember PRPH:UnaffiliatedInvestorLoanMember 2025-06-22 0000868278 PRPH:FirstAugust2025NoteMember us-gaap:LoansPayableMember 2025-08-01 2025-08-01 0000868278 PRPH:FirstAugust2025NoteMember us-gaap:LoansPayableMember 2025-08-01 0000868278 PRPH:FirstAugust2025NoteMember us-gaap:LoansPayableMember 2026-01-23 0000868278 PRPH:FirstAugust2025NoteMember us-gaap:LoansPayableMember 2026-01-23 2026-01-23 0000868278 PRPH:FirstAugust2025NoteMember us-gaap:LoansPayableMember 2026-01-01 2026-03-31 0000868278 PRPH:FirstAugust2025NoteMember us-gaap:LoansPayableMember 2026-03-31 0000868278 PRPH:FirstAugust2025NoteMember us-gaap:ConvertibleDebtMember 2026-03-31 0000868278 PRPH:SecondAugust2025NoteMember us-gaap:LoansPayableMember 2025-08-14 2025-08-14 0000868278 PRPH:SecondAugust2025NoteMember us-gaap:LoansPayableMember 2025-08-14 0000868278 PRPH:ThirdAugust2025NotesMember us-gaap:LoansPayableMember 2025-09-11 0000868278 PRPH:ThirdAugust2025NotesMember us-gaap:LoansPayableMember 2025-08-01 2025-09-11 0000868278 PRPH:ThirdAugust2025NotesMember us-gaap:LoansPayableMember 2026-01-01 2026-03-31 0000868278 PRPH:ThirdAugust2025NoteMember us-gaap:LoansPayableMember 2026-01-23 0000868278 PRPH:ThirdAugust2025NoteMember us-gaap:LoansPayableMember 2026-01-23 2026-01-23 0000868278 PRPH:ThirdAugust2025NoteMember us-gaap:LoansPayableMember 2026-01-01 2026-03-31 0000868278 PRPH:ThirdAugust2025NoteMember us-gaap:LoansPayableMember 2026-03-31 0000868278 PRPH:ThirdAugust2025NoteMember us-gaap:ConvertibleDebtMember 2026-03-31 0000868278 PRPH:November2025NoteMember us-gaap:LoansPayableMember 2025-11-06 2025-11-06 0000868278 PRPH:November2025NoteMember us-gaap:LoansPayableMember 2025-11-06 0000868278 PRPH:November2025NoteMember us-gaap:LoansPayableMember 2026-01-01 2026-03-31 0000868278 PRPH:FirstDecember2025NoteMember us-gaap:LoansPayableMember 2025-12-22 2025-12-22 0000868278 PRPH:FirstDecember2025NoteMember us-gaap:LoansPayableMember 2025-12-22 0000868278 PRPH:FirstDecember2025NoteMember us-gaap:LoansPayableMember 2026-01-01 2026-03-31 0000868278 PRPH:SecondDecember2025NoteMember us-gaap:LoansPayableMember 2025-12-26 2025-12-26 0000868278 PRPH:SecondDecember2025NoteMember us-gaap:LoansPayableMember 2025-12-26 0000868278 PRPH:SecondDecember2025NoteMember us-gaap:LoansPayableMember 2026-01-01 2026-03-31 0000868278 PRPH:August2025FutureReceiptsFinancingAgreementsMember us-gaap:LoansPayableMember 2025-08-22 0000868278 PRPH:August2025FutureReceiptsFinancingAgreementsMember us-gaap:LoansPayableMember 2025-08-25 2025-08-25 0000868278 PRPH:August2025FutureReceiptsFinancingAgreementsMember us-gaap:LoansPayableMember 2025-08-25 0000868278 PRPH:LibertasFinancingAgreementMember us-gaap:LoansPayableMember 2025-08-25 2025-08-25 0000868278 PRPH:August2025FutureReceiptsFinancingAgreementsMember us-gaap:LoansPayableMember 2025-08-22 2025-08-22 0000868278 PRPH:AugustWarrantsMember PRPH:August2025FutureReceiptsFinancingAgreementsMember us-gaap:LoansPayableMember 2025-08-22 0000868278 PRPH:AugustWarrantsMember PRPH:August2025FutureReceiptsFinancingAgreementsMember us-gaap:LoansPayableMember 2025-08-22 2025-08-22 0000868278 PRPH:August2025FutureReceiptsFinancingAgreementsMember us-gaap:LoansPayableMember 2026-01-01 2026-03-31 0000868278 PRPH:August2025FutureReceiptsFinancingAgreementsMember us-gaap:LoansPayableMember 2026-03-31 0000868278 PRPH:September2025FutureReceiptsFinancingAgreementsMember us-gaap:LoansPayableMember 2025-09-29 2025-09-29 0000868278 PRPH:September2025FutureReceiptsFinancingAgreementsMember us-gaap:LoansPayableMember 2025-09-29 0000868278 PRPH:September2025FutureReceiptsFinancingAgreementsMember us-gaap:LoansPayableMember 2026-01-01 2026-03-31 0000868278 PRPH:September2025FutureReceiptsFinancingAgreementsMember us-gaap:LoansPayableMember 2026-03-31 0000868278 PRPH:July2025NotesMember us-gaap:ConvertibleNotesPayableMember 2025-07-22 0000868278 PRPH:July2025NotesMember us-gaap:ConvertibleNotesPayableMember 2025-07-22 2025-07-22 0000868278 PRPH:JulyWarrantsMember PRPH:July2025NotesMember us-gaap:ConvertibleNotesPayableMember 2025-07-22 0000868278 PRPH:JulyWarrantsMember PRPH:July2025NotesMember us-gaap:ConvertibleNotesPayableMember 2025-07-22 2025-07-22 0000868278 PRPH:July2025NotesMember us-gaap:LoansPayableMember 2026-01-01 2026-03-31 0000868278 PRPH:July2025NotesMember us-gaap:LoansPayableMember 2026-03-31 0000868278 PRPH:ERCClaimAndRiskParticipationAgreementMember 2023-08-31 0000868278 PRPH:A1861AcquisitionLLCMember PRPH:ERCClaimAndRiskParticipationAgreementMember 2024-09-16 2024-09-16 0000868278 PRPH:A1861AcquisitionLLCMember PRPH:ERCClaimAndRiskParticipationAgreementMember 2024-09-16 0000868278 PRPH:A1861AcquisitionLLCMember PRPH:ERCClaimMember PRPH:ERCClaimAndRiskParticipationAgreementMember 2025-01-01 2025-12-31 0000868278 PRPH:A1861AcquisitionLLCMember PRPH:ERCClaimMember PRPH:ERCClaimAndRiskParticipationAgreementMember 2025-12-31 0000868278 PRPH:A1861AcquisitionLLCMember PRPH:ERCClaimMember PRPH:ERCClaimAndRiskParticipationAgreementMember 2026-03-31 0000868278 PRPH:TwentyTwentyFourCollateralizedLoanAgreementMember 2024-11-21 0000868278 PRPH:TwentyTwentyFourCollateralizedLoanAgreementMember 2024-11-21 2024-11-21 0000868278 PRPH:TwentyTwentyFourCollateralizedLoanAgreementMember 2026-03-31 0000868278 PRPH:TwentyTwentyFiveCollateralizedLoanAgreementMember 2025-10-14 2025-10-14 0000868278 PRPH:TwentyTwentyFiveCollateralizedLoanAgreementMember 2025-10-14 0000868278 PRPH:TwentyTwentyFiveCollateralizedLoanAgreementMember 2026-03-31 0000868278 PRPH:TwentyTwentyFiveCollateralizedLoanAgreementMember 2026-01-01 2026-03-31 0000868278 2025-01-01 2025-12-31 0000868278 PRPH:WestParkCapitalIncMember PRPH:AtTheMarketOfferingMember 2025-12-19 2025-12-19 0000868278 PRPH:AtTheMarketOfferingMember 2026-01-01 2026-03-31 0000868278 PRPH:StockPurchaseAgreementMember 2026-01-16 0000868278 us-gaap:CommonStockMember 2026-01-16 2026-01-16 0000868278 us-gaap:CommonStockMember 2026-01-16 0000868278 PRPH:TwoThousandsTwentyFiveDirectorsPlanMember 2025-09-09 2025-09-09 0000868278 PRPH:TwoThousandsTwentyFiveDirectorsPlanMember 2026-01-01 2026-03-31 0000868278 PRPH:TwoThousandsTwentyFiveDirectorsPlanMember 2026-03-31 0000868278 PRPH:TwoThousandsTwentyFiveDirectorsPlanMember 2022-05-19 2022-05-19 0000868278 PRPH:AmendedTwoThousandsTwentyTwoDirectorsPlanMember 2023-06-16 0000868278 PRPH:TwoThousandsTwentyTwoDirectorsPlanMember 2025-09-08 0000868278 PRPH:TwoThousandsTwentyFivePlanMember 2025-09-09 2025-09-09 0000868278 PRPH:TwoThousandsTwentyFivePlanMember 2026-03-31 0000868278 PRPH:TwoThousandsTwentyTwoPlanMember 2022-05-09 0000868278 PRPH:TwoThousandsTwentyTwoPlanMember 2025-09-08 0000868278 us-gaap:WarrantMember 2026-03-31 0000868278 us-gaap:WarrantMember 2025-12-31 0000868278 us-gaap:WarrantMember 2025-01-01 2025-12-31 0000868278 us-gaap:WarrantMember 2026-01-01 2026-03-31 0000868278 PRPH:LinebackerLicenseAgreementsMember 2022-07-19 2022-07-19 0000868278 PRPH:NewDrugApplicationMember PRPH:LinebackerLicenseAgreementsMember 2022-07-19 2022-07-19 0000868278 srt:MinimumMember PRPH:BESmartLicenseAgreementsMember 2025-03-31 2025-03-31 0000868278 srt:MaximumMember PRPH:BESmartLicenseAgreementsMember 2025-03-31 2025-03-31 0000868278 PRPH:BESmartLicenseAgreementsMember 2025-03-31 2025-03-31 0000868278 PRPH:CPMMember PRPH:OldBridgeNewJerseyMember 2020-10-23 0000868278 PRPH:CPMMember PRPH:OldBridgeNewJerseyMember 2020-10-23 2020-10-23 0000868278 PRPH:NewYorkSecondFloorLeaseMember 2025-03-01 2025-03-01 0000868278 PRPH:NewYorkFirstFloorLeaseMember 2022-06-10 0000868278 2023-04-19 0000868278 2023-07-21 0000868278 PRPH:DiagnosticServicesSegmentMember 2026-01-01 2026-03-31 0000868278 PRPH:DiagnosticServicesSegmentMember 2025-01-01 2025-03-31 0000868278 PRPH:ConsumerProductsSegmentMember 2026-01-01 2026-03-31 0000868278 PRPH:ConsumerProductsSegmentMember 2025-01-01 2025-03-31 0000868278 PRPH:UnallocatedCorporateMember 2026-01-01 2026-03-31 0000868278 PRPH:UnallocatedCorporateMember 2025-01-01 2025-03-31 0000868278 PRPH:ConsumerProductsSegmentMember 2026-03-31 0000868278 PRPH:ConsumerProductsSegmentMember 2025-12-31 0000868278 PRPH:UnallocatedCorporateMember 2026-03-31 0000868278 PRPH:UnallocatedCorporateMember 2025-12-31 0000868278 PRPH:CommonStockPurchaseWarrantsMember 2026-01-01 2026-03-31 0000868278 PRPH:CommonStockPurchaseWarrantsMember 2025-01-01 2025-03-31 0000868278 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0000868278 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0000868278 us-gaap:ConvertibleDebtSecuritiesMember 2026-01-01 2026-03-31 0000868278 us-gaap:ConvertibleDebtSecuritiesMember 2025-01-01 2025-03-31 0000868278 srt:ChiefOperatingOfficerMember PRPH:ConsultingServicesMember us-gaap:RelatedPartyMember 2025-01-01 2025-03-31 0000868278 srt:ChiefOperatingOfficerMember PRPH:ConsultingServicesMember us-gaap:RelatedPartyMember 2025-01-01 2025-09-30 0000868278 srt:ChiefOperatingOfficerMember PRPH:ConsultingServicesMember us-gaap:RelatedPartyMember 2024-01-01 2024-09-30 0000868278 PRPH:FormerChiefOperatingOfficerMember us-gaap:RelatedPartyMember 2026-03-31 0000868278 srt:ChiefExecutiveOfficerMember 2025-06-22 0000868278 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember 2025-01-16 2025-01-16 0000868278 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember PRPH:PMINoteMember 2025-01-16 2025-01-16 0000868278 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember PRPH:CapitalLeasesMember 2025-01-16 2025-01-16 0000868278 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember PRPH:CurrentAndAccruedPayablesMember 2025-01-16 2025-01-16 0000868278 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember PRPH:ExistingLoanFromAffiliatesMember 2025-01-16 2025-01-16 0000868278 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember PRPH:AccruedInterestMember 2025-01-16 2025-01-16 0000868278 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember 2025-01-01 2025-03-31 0000868278 PRPH:PDXMember 2025-09-22 0000868278 PRPH:PDXMember srt:AffiliatedEntityMember 2025-09-30 0000868278 srt:AffiliatedEntityMember 2026-03-31 0000868278 srt:AffiliatedEntityMember 2025-12-31 0000868278 us-gaap:FairValueInputsLevel1Member 2026-03-31 0000868278 us-gaap:FairValueInputsLevel2Member 2026-03-31 0000868278 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0000868278 us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0000868278 us-gaap:FairValueInputsLevel1Member 2025-12-31 0000868278 us-gaap:FairValueInputsLevel2Member 2025-12-31 0000868278 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0000868278 us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0000868278 us-gaap:DerivativeMember 2024-12-31 0000868278 PRPH:JulyTwoThousandTwentyFiveNotesMember us-gaap:DerivativeMember 2025-01-01 2025-09-30 0000868278 us-gaap:DerivativeMember 2025-01-01 2025-09-30 0000868278 PRPH:AugustFutureFinancingAgreementMember us-gaap:DerivativeMember 2025-01-01 2025-09-30 0000868278 us-gaap:DerivativeMember 2025-09-30 0000868278 us-gaap:MeasurementInputExercisePriceMember 2025-09-09 0000868278 us-gaap:MeasurementInputExercisePriceMember 2025-09-30 0000868278 us-gaap:MeasurementInputExpectedTermMember 2025-09-09 0000868278 us-gaap:MeasurementInputExpectedTermMember 2025-09-30 0000868278 us-gaap:MeasurementInputPriceVolatilityMember 2025-09-09 0000868278 us-gaap:MeasurementInputPriceVolatilityMember 2025-09-30 0000868278 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-09-09 0000868278 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-09-30 0000868278 us-gaap:MeasurementInputExpectedDividendRateMember 2025-09-09 0000868278 us-gaap:MeasurementInputExpectedDividendRateMember 2025-09-30 0000868278 us-gaap:SubsequentEventMember 2026-06-04 2026-06-04 iso4217:USD shares iso4217:USD shares pure PRPH:Integer utr:sqft PRPH:Segment false --12-31 Q1 0000868278

10-Q true 2026-03-31 2026 false 000-21617 ProPhase Labs, Inc. DE 23-2577138 626 RXR Plaza 6th Floor Uniondale NY 11556 (516) 989-0763 Common Stock, par value $0.0005 PRPH No Yes Non-accelerated Filer true false false 0.0005 14016204

31000

90000

1543000

1536000

70000

1469000

1454000

3113000

3150000

1709000

2032000

43266000

43491000

150000

61000

6522000

7167000

3968000

2000

58730000

59871000

14169000

12961000

27572000

27600000

27572000

27600000

50000

3054000

2824000

329000

451000

4547000

4418000

67000

132000

558000

493000

558000

493000

511000

157000

304000

244000

490000

50000

1840000

1501000

793000

281000

2731000

2659000

56108000

53081000

2000000

788000

643000

448000

639000

3236000

3282000

59344000

56363000

1000000

0.0005

1000000000

0.0005

14016024

8966406

7000

4000

127710000

126481000

-78490000

-73136000

869208

49643000

-198000

-614000

3508000

58730000

59871000

600000 true

478000

1431000

311000

905000

167000

526000

2772000

4092000

97000

2772000

4189000

-2605000

-3663000

-225000

-86000

651000

539000

-278000

-431000

-12000

6000

-129000

-45000

-3980000

-4678000

1374000

-5354000

-4678000

-102000

8746000

8644000

-5354000

3966000

-0.43

-1.33

2.45

-0.43

1.13

12317000

3523000

12317000

3523000

8966405

4000

126481000

-73136000

-49643000

-198000

3508000

30000

163900

41000

549105

155000 32000 32000

4181614

3000

766000

769000

390000

-5354000

14016024

7000

127710000

-78490000

-49643000

-198000

-614000

29874029

23000

129921000

-58393000

-64000000

-198000

7353000

29874029

23000

129921000

-58393000

-64000000

-198000

7353000

75000

11315000

6000

-10605000

-480000

14357000

3278000

352176

455000

521000

3966000

41541205

29000

119837000

-480000

-54427000

-49643000

-198000

15118000

41541205

29000

119837000

-480000

-54427000

-49643000

-198000

15118000

-5354000

3966000

8644000

-5354000

-4678000

962000

1482000

476000

372000

121000

-225000

-12000

6000

-45000

390000

521000

-86000

-278000

-431000

7000

146000

2000

104000

636000

1180000

-391000

12000

484000

-143000

39000

9000

512000

-523000

79000

-452000

-748000

-3978000

597000

-748000

-3381000

12000

53000

12000

53000

800000

12000

853000

41000

3278000

288000

204000

392000

44000

1509000

677000

1973000

-35000

677000

1938000

-59000

-590000

90000

678000

31000

88000

256000

30000

376000

158000 769000

<p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zU5Fhsa3Mpue" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Note 1 - Organization and Business ProPhase Labs, Inc. (“ProPhase”, “we”, “us”, “our” or the “Company”) is a next-generation biotech, genomics and consumer products company. We are also focused on licensing, developing and commercializing novel drugs, dietary supplements, compounds and diagnostics. Our wholly-owned subsidiary, ProPhase Diagnostics, Inc., and two indirectly wholly-owned subsidiaries, ProPhase Diagnostics NY, Inc. and ProPhase Diagnostics NJ, Inc., ceased providing COVID-19 diagnostic testing in May 2025. ProPhase Diagnostics NJ, Inc. still leases the laboratory space in Old Bridge, New Jersey. The labs were forced to cease diagnostic testing when medical insurance carriers ceased paying COVID-19 diagnostic testing claims. On September 22, 2025, the three lab entities filed for a Chapter 11 reorganization in United States Bankruptcy Court for the District of New Jersey. On September 30, 2025, the Court granted the motion for joint administration. The bankruptcy filing is the next step in the Company’s legal advisor, Crown Medical Collections, strategic initiative to collect what the Company believes could be tens of millions of dollars in unpaid insurance claims. The Company believes one objective of the bankruptcy filing is to streamline and accelerate recovery of the unpaid insurance claims the Company believes were lawfully owed for approved and completed testing services. In August 2021, the Company acquired Nebula Genomics, Inc. (“Nebula”), a privately owned personal genomics company, through our wholly-owned subsidiary, ProPhase Precision Medicine Inc. Nebula focuses on genomics sequencing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in deoxyribonucleic acid (“DNA”). The data obtained from genomic sequencing can be used to help identify inherited disorders and tendencies, help predict disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression. At this time, the Company is taking steps to grow its genomics businesses while also continuing to explore the potential sale of Nebula. The Company’s wholly-owned subsidiary, DNA Complete, Inc. (“DNA Complete”), which was formed on September 24, 2024, for the offering of whole genome sequencing and related services. DNA Complete sequences specimens at Nebula as well as at other laboratories. DNA Complete focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in deoxyribonucleic acid (“DNA”). The data obtained from genomic sequencing may help to identify inherited disorders and tendencies, predict disease risk, identify expected drug response, and characterize genetic mutations, including those that drive cancer progression. DNA Complete currently offers DNA Complete’s whole genome sequencing products direct-to-consumers online with plans to sell in food, drug and mass retail stores and to provide testing for universities conducting genomic research. The Company’s wholly owned subsidiary, ProPhase BioPharma, Inc. (“PBIO”), was formed in June 2022, for the licensing, development and commercialization of novel drugs, dietary supplements and compounds. Licensed compounds currently include Equivir (a OTC, dietary supplement candidate) and Equivir G (prescription drug (“Rx”) candidate), two broad-based anti-virals, and Linebacker LB-1 and LB-2, two small molecule proviral integration site for moloney murine leukemia virus (“PIM”) kinase inhibitors. The Company also owns the exclusive rights to the BE-Smart™ Esophageal Pre-Cancer Diagnostic Screening test and related intellectual property (“IP”) assets. In connection with the activities of PBIO, in January 2023, the Company acquired exclusive rights to BE-Smart™ Esophageal Pre-Cancer Diagnostic Screening test and related IP assets. The BE-Smart™ test is focused on the early detection of esophageal cancer, and is intended to provide health care providers and patients with data to help determine treatment options. The development of these novel drugs and compounds is highly dependent on how each performs during the testing and development stage, the demand for these product and services once entered into the marketplace, our marketing and service capabilities and our ability to comply with applicable regulatory requirements. The Company also owns a dietary supplements business under the TK Supplements® brand. The TK Supplements® product line includes Legendz XL®, a male sexual enhancement and Triple Edge XL®, an energy and stamina support product. ProPhase Labs, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (unaudited) Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As of March 31, 2026, the Company had minimal cash resources and a significant working capital deficit. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. Management’s plans do not alleviate this substantial doubt. Management has evaluated the significance of these conditions and has developed plans intended to improve liquidity and support operations. Management’s plans include continuing efforts to reduce operating expenditures and preserve cash resources; focusing operations on its remaining core businesses, including genomics and biotechnology activities; pursuing collection and recovery efforts related to outstanding receivables and other claims; evaluating strategic alternatives including potential asset monetization opportunities, partnerships, licensing arrangements and other financing alternatives; and continuing initiatives intended to improve operating efficiency and revenue generation. Management’s plans are subject to numerous uncertainties, many of which are outside the Company’s control, including the timing and availability of external financing, realization of anticipated collections and recovery efforts, and achievement of projected operating results. Accordingly, management has concluded that these plans do not alleviate the substantial doubt regarding the Company’s ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result should the Company be unable to continue as a going concern.

3 2 2

Note 2 - Summary of Significant Accounting Policies Basis of Presentation The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles accepted in the United States of America (“GAAP”) for interim financial statements and the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our audited consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and other comprehensive loss and consolidated cash flows, for the periods indicated, have been made. The results of operations for the three months ended March 31, 2026 are not necessarily indicative of operating results that may be achieved over the course of the full year. Use of Estimates The preparation of condensed consolidated financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include revenue recognition and the impact of the variable consideration of diagnostic test reimbursement rates, the allowance for credit losses and billing errors, allowances, slow moving and/or dated inventory and associated provisions, the potential impairment of long-lived assets, stock based compensation valuations, income tax asset valuations and assumptions related to accrued advertising. Our estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the condensed consolidated financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates. ProPhase Labs, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (unaudited) Deconsolidation of Subsidiary A subsidiary is deconsolidated from the Company’s financial statements when the Company no longer has a controlling financial interest in the subsidiary. This generally occurs when the Company loses control through a sale, transfer, or other means, including the expiry of a contractual agreement. Upon deconsolidation, the Company derecognizes the assets and liabilities of the of the subsidiary from the consolidated balance sheet at their carrying amounts at the date when control is lost. Any retained noncontrolling equity investment in the former subsidiary is remeasured to its fair value at the date control is lost. This fair value becomes the initial carrying amount of the retained investment. See Note 14 for discussion regarding the voluntary bankruptcy filing by the Company’s fully owned subsidiaries. Discontinued Operations The Company presents discontinued operations when there is a disposal of a component or a group of components that represents a strategic shift that will have a major effect on operations and financial results. The results of discontinued operations are reported in net income (loss) from discontinued operations in the condensed consolidated statements of operations for all periods presented, commencing in the period in which the business is either disposed of or is classified as held for sale, including any gain or loss recognized on closing or adjustment of the carrying amount to fair value less costs to sell. Assets and liabilities related to a business classified as held for sale or meets the criteria for discontinued operations are segregated in the consolidated balance sheets for the current and prior periods presented. Cash flows for continuing and discontinued operations are segregated in the consolidated statements of cash flows for the current and prior periods. Certain prior period balances related to the Company’s reportable segments and discontinued operations have been reclassified to conform to the current presentation in the consolidated financial statements have been prepared by management without audit and should be read in conjunction with our audited consolidated financial statements, including the accompanying notes appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. In the opinion of management, all adjustments necessary for a fair presentation of the notes to the condensed consolidated financial statements are presented on a continuing operations basis unless otherwise noted. Reclassifications The Company has reclassified certain amounts on the condensed consolidated balance sheets, condensed consolidated statements of operations and comprehensive loss and condensed consolidated statements of cash flows to conform to current period presentation. Fair Value of Financial Instruments We measure assets and liabilities at fair value based on expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale date of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level. The following are the hierarchical levels of inputs to measure fair value: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.</td></tr></table> The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable, accounts payable, and unsecured note payable, approximate their fair values because of the short-term nature of these instruments. We account for our marketable securities at fair value, with the net unrealized gains or losses of marketable debt securities reported as a component of accumulated other comprehensive income or loss and marketable equity securities change in fair value reported on the consolidated statement of operations. We measure the fair value of financial instruments, such as derivatives, on an ongoing basis. See Note 15, “Fair Value Measurements” for more information Goodwill Goodwill represents the excess of the fair value of the consideration transferred over the fair value of the underlying identifiable assets and liabilities acquired in a business combination. Goodwill and intangible assets deemed to have an indefinite life are not amortized, but instead are assessed for impairment annually. Additionally, if an event or change in circumstances occurs that would more likely than not reduce the fair value of the reporting unit below its carrying value, we would evaluate goodwill at that time. Revenue Recognition and Accounts Receivable The Company recognizes revenues in accordance with Financial Accounting Standards Board (“FASB”)’s Accounting Standards Codification (“ASC”) 606, Revenues from Contracts with Customers. The Company recognizes revenue that represents the transfer of promised goods or services to customers at an amount that reflects the consideration that is expected to be received in exchange for those goods or services. The Company recognizes revenue when performance obligations with our customers have been satisfied. At contract inception, we evaluate the contract to determine if revenue should be recognized using the following five steps: (1) identify the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ProPhase Labs, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (unaudited) The Company carries its accounts receivable at cost less an allowance for credit losses. Allowances for credit losses are based upon the Company’s judgment regarding collectability. On a periodic basis, the Company evaluates its receivables and establish an allowance for credit losses, based on a history of past write-offs, collections, current credit conditions or generally accepted future trends in the industry and/or local economy. Accounts are written off as uncollectible at the time we determine that collections are unlikely. The reserve is not intended to address return activity or disputed balances with ongoing customers, as this should be addressed in a reserve for credit memos with a corresponding charge to revenue. Income Taxes The Company recognizes deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse. The provision for, or benefit from, income taxes includes deferred taxes resulting from the temporary differences in income for financial and tax purposes using the liability method. Future realization of deferred income tax assets requires sufficient taxable income within the carryback, carryforward period available under tax law. We evaluate, on a quarterly basis whether, based on all available evidence, it is probable that the deferred income tax assets are realizable. Valuation allowances are established when it is more likely than not that the tax benefit of the deferred tax asset will not be realized. The evaluation, as prescribed by ASC 740-10, “Income Taxes,” includes the consideration of all available evidence, both positive and negative, regarding historical operating results including recent years with reported losses, the estimated timing of future reversals of existing taxable temporary differences, estimated future taxable income exclusive of reversing temporary differences and carryforwards, and potential tax planning strategies which may be employed to prevent an operating loss or tax credit carryforward from expiring unused. The Company accounts for uncertainties in income taxes under the provisions of FASB ASC 740-10-05 (the “Subtopic”). The Subtopic clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The Subtopic prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Subtopic provides guidance on the de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Recently Adopted Accounting Standards In November 2024, the FASB issued ASU 2024-04, Debt-Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments. This standard clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion and the application of the induced conversion guidance to a conversion debt instrument. It also clarifies that the incorporation, elimination, or modification of a daily volume-weighted average price (“VWAP”) formula does not automatically cause a settlement to be accounted for as an extinguishment. This standard will become effective on a prospective or retrospective basis for interim reporting periods and annual periods beginning after December 15, 2025. Early adoption is permitted. The Company adopted this guidance effective January 1, 2026 on a prospective basis. The adoption of this standard did not have a material impact on the Company’s financial position, results of operations, or cash flows. Recently Issued Accounting Standards, Not Yet Adopted In November 2024, the FASB issued ASU No. 2024-03 (“ASU 2024-03”), Disaggregation of Income Statement Expenses (DISE) which requires disaggregated disclosure of income statement expenses for public business entities. The standard requires public business entities to disclose disaggregated information about specific natural expense categories underlying certain income statement expense line items that are considered relevant. The FASB also issued ASU No. 2025-01 (“ASU 2025-01”), Clarifying the Effective Date, which clarifies the adoption date of ASU 2024-03 as annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating the potential effect of this accounting standard update on its consolidated financial statements and related disclosures. In September 2025, the FASB issued ASU No. 2025 - 06, Intangibles - Goodwill and Other - Internal - Use Software (“ASU 2025 – 06”), which amends the guidance for accounting for software costs to reflect current software development practices, including iterative and agile methodologies, by removing references to development stages. It also clarifies the criteria for capitalization, which begins when both of the following occur: (1) management has authorized and committed to funding the software project and (2) it is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025 - 06 is effective for fiscal years beginning after December 15, 2027, and interim periods within those fiscal years. Early adoption is permitted. The amendments may be applied either prospectively, retrospectively, or utilizing a modified transition approach. The Company is currently assessing the impact of ASU 2025 - 06 on its condensed consolidated financial statements and disclosures. ProPhase Labs, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (unaudited) In September 2025, the FASB issued ASU 2025-07. This update clarifies the application of derivative accounting to certain contracts and refines the guidance for share-based noncash consideration received from customers. Specifically, ASU 2025-07 introduces a scope exception for contracts that are not exchange-traded and whose underlying is tied to operations or activities specific to one party. It also clarifies that share-based noncash consideration from a customer should initially be accounted for under Topic 606 until the right to receive or retain such consideration becomes unconditional, at which point financial instruments guidance may apply. The effective date for the standard is for fiscal years beginning after December 15, 2026 and interim periods within those fiscal years. Early adoption is permitted. The amendments in ASU 2025-07 should be applied either prospectively or by utilizing a modified retrospective approach. The Company is currently assessing the impact on the Company’s condensed consolidated financial statements and disclosures. In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. This update clarifies interim disclosure requirements and centralizes such requirements within Topic 270. Among other changes, ASU 2025-11 introduces a disclosure principle requiring entities to provide information about significant events or changes since the end of the last annual reporting period that have a material impact, clarifies when duplicative annual disclosures may be omitted from interim reports, and aligns interim reporting requirements with applicable SEC guidance for registrants. This guidance is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The amendments in ASU 2025-11 should be applied prospectively. The Company is currently assessing the impact on the Company’s condensed consolidated financial statements and disclosures. In December 2025, the FASB issued ASU 2025-12, Codification Improvements. This update addresses shareholder suggestions on the Accounting Standards Codification and makes other incremental improvements to U.S. GAAP. The amendments make codification updates to a broad range of topics arising from technical corrections, unintended application of the codification, clarifications and other minor improvements. This guidance is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods within those annual periods. Early adoption is permitted and may be elected on an issue-by-issue basis. The amendments in ASU 2025-12 are to be applied prospectively. The Company is currently assessing the impact on the Company’s condensed consolidated financial statements and disclosures.

Basis of Presentation The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles accepted in the United States of America (“GAAP”) for interim financial statements and the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our audited consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and other comprehensive loss and consolidated cash flows, for the periods indicated, have been made. The results of operations for the three months ended March 31, 2026 are not necessarily indicative of operating results that may be achieved over the course of the full year.

Use of Estimates The preparation of condensed consolidated financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include revenue recognition and the impact of the variable consideration of diagnostic test reimbursement rates, the allowance for credit losses and billing errors, allowances, slow moving and/or dated inventory and associated provisions, the potential impairment of long-lived assets, stock based compensation valuations, income tax asset valuations and assumptions related to accrued advertising. Our estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the condensed consolidated financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates. ProPhase Labs, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (unaudited)

Deconsolidation of Subsidiary A subsidiary is deconsolidated from the Company’s financial statements when the Company no longer has a controlling financial interest in the subsidiary. This generally occurs when the Company loses control through a sale, transfer, or other means, including the expiry of a contractual agreement. Upon deconsolidation, the Company derecognizes the assets and liabilities of the of the subsidiary from the consolidated balance sheet at their carrying amounts at the date when control is lost. Any retained noncontrolling equity investment in the former subsidiary is remeasured to its fair value at the date control is lost. This fair value becomes the initial carrying amount of the retained investment. See Note 14 for discussion regarding the voluntary bankruptcy filing by the Company’s fully owned subsidiaries.

Discontinued Operations The Company presents discontinued operations when there is a disposal of a component or a group of components that represents a strategic shift that will have a major effect on operations and financial results. The results of discontinued operations are reported in net income (loss) from discontinued operations in the condensed consolidated statements of operations for all periods presented, commencing in the period in which the business is either disposed of or is classified as held for sale, including any gain or loss recognized on closing or adjustment of the carrying amount to fair value less costs to sell. Assets and liabilities related to a business classified as held for sale or meets the criteria for discontinued operations are segregated in the consolidated balance sheets for the current and prior periods presented. Cash flows for continuing and discontinued operations are segregated in the consolidated statements of cash flows for the current and prior periods. Certain prior period balances related to the Company’s reportable segments and discontinued operations have been reclassified to conform to the current presentation in the consolidated financial statements have been prepared by management without audit and should be read in conjunction with our audited consolidated financial statements, including the accompanying notes appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. In the opinion of management, all adjustments necessary for a fair presentation of the notes to the condensed consolidated financial statements are presented on a continuing operations basis unless otherwise noted.

Reclassifications The Company has reclassified certain amounts on the condensed consolidated balance sheets, condensed consolidated statements of operations and comprehensive loss and condensed consolidated statements of cash flows to conform to current period presentation.

Fair Value of Financial Instruments We measure assets and liabilities at fair value based on expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale date of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level. The following are the hierarchical levels of inputs to measure fair value: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.</td></tr></table> The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable, accounts payable, and unsecured note payable, approximate their fair values because of the short-term nature of these instruments. We account for our marketable securities at fair value, with the net unrealized gains or losses of marketable debt securities reported as a component of accumulated other comprehensive income or loss and marketable equity securities change in fair value reported on the consolidated statement of operations. We measure the fair value of financial instruments, such as derivatives, on an ongoing basis. See Note 15, “Fair Value Measurements” for more information

Goodwill Goodwill represents the excess of the fair value of the consideration transferred over the fair value of the underlying identifiable assets and liabilities acquired in a business combination. Goodwill and intangible assets deemed to have an indefinite life are not amortized, but instead are assessed for impairment annually. Additionally, if an event or change in circumstances occurs that would more likely than not reduce the fair value of the reporting unit below its carrying value, we would evaluate goodwill at that time.

Revenue Recognition and Accounts Receivable The Company recognizes revenues in accordance with Financial Accounting Standards Board (“FASB”)’s Accounting Standards Codification (“ASC”) 606, Revenues from Contracts with Customers. The Company recognizes revenue that represents the transfer of promised goods or services to customers at an amount that reflects the consideration that is expected to be received in exchange for those goods or services. The Company recognizes revenue when performance obligations with our customers have been satisfied. At contract inception, we evaluate the contract to determine if revenue should be recognized using the following five steps: (1) identify the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ProPhase Labs, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (unaudited) The Company carries its accounts receivable at cost less an allowance for credit losses. Allowances for credit losses are based upon the Company’s judgment regarding collectability. On a periodic basis, the Company evaluates its receivables and establish an allowance for credit losses, based on a history of past write-offs, collections, current credit conditions or generally accepted future trends in the industry and/or local economy. Accounts are written off as uncollectible at the time we determine that collections are unlikely. The reserve is not intended to address return activity or disputed balances with ongoing customers, as this should be addressed in a reserve for credit memos with a corresponding charge to revenue.

Income Taxes The Company recognizes deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse. The provision for, or benefit from, income taxes includes deferred taxes resulting from the temporary differences in income for financial and tax purposes using the liability method. Future realization of deferred income tax assets requires sufficient taxable income within the carryback, carryforward period available under tax law. We evaluate, on a quarterly basis whether, based on all available evidence, it is probable that the deferred income tax assets are realizable. Valuation allowances are established when it is more likely than not that the tax benefit of the deferred tax asset will not be realized. The evaluation, as prescribed by ASC 740-10, “Income Taxes,” includes the consideration of all available evidence, both positive and negative, regarding historical operating results including recent years with reported losses, the estimated timing of future reversals of existing taxable temporary differences, estimated future taxable income exclusive of reversing temporary differences and carryforwards, and potential tax planning strategies which may be employed to prevent an operating loss or tax credit carryforward from expiring unused. The Company accounts for uncertainties in income taxes under the provisions of FASB ASC 740-10-05 (the “Subtopic”). The Subtopic clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The Subtopic prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Subtopic provides guidance on the de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.

Recently Adopted Accounting Standards In November 2024, the FASB issued ASU 2024-04, Debt-Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments. This standard clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion and the application of the induced conversion guidance to a conversion debt instrument. It also clarifies that the incorporation, elimination, or modification of a daily volume-weighted average price (“VWAP”) formula does not automatically cause a settlement to be accounted for as an extinguishment. This standard will become effective on a prospective or retrospective basis for interim reporting periods and annual periods beginning after December 15, 2025. Early adoption is permitted. The Company adopted this guidance effective January 1, 2026 on a prospective basis. The adoption of this standard did not have a material impact on the Company’s financial position, results of operations, or cash flows.

Recently Issued Accounting Standards, Not Yet Adopted In November 2024, the FASB issued ASU No. 2024-03 (“ASU 2024-03”), Disaggregation of Income Statement Expenses (DISE) which requires disaggregated disclosure of income statement expenses for public business entities. The standard requires public business entities to disclose disaggregated information about specific natural expense categories underlying certain income statement expense line items that are considered relevant. The FASB also issued ASU No. 2025-01 (“ASU 2025-01”), Clarifying the Effective Date, which clarifies the adoption date of ASU 2024-03 as annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating the potential effect of this accounting standard update on its consolidated financial statements and related disclosures. In September 2025, the FASB issued ASU No. 2025 - 06, Intangibles - Goodwill and Other - Internal - Use Software (“ASU 2025 – 06”), which amends the guidance for accounting for software costs to reflect current software development practices, including iterative and agile methodologies, by removing references to development stages. It also clarifies the criteria for capitalization, which begins when both of the following occur: (1) management has authorized and committed to funding the software project and (2) it is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025 - 06 is effective for fiscal years beginning after December 15, 2027, and interim periods within those fiscal years. Early adoption is permitted. The amendments may be applied either prospectively, retrospectively, or utilizing a modified transition approach. The Company is currently assessing the impact of ASU 2025 - 06 on its condensed consolidated financial statements and disclosures. ProPhase Labs, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (unaudited) In September 2025, the FASB issued ASU 2025-07. This update clarifies the application of derivative accounting to certain contracts and refines the guidance for share-based noncash consideration received from customers. Specifically, ASU 2025-07 introduces a scope exception for contracts that are not exchange-traded and whose underlying is tied to operations or activities specific to one party. It also clarifies that share-based noncash consideration from a customer should initially be accounted for under Topic 606 until the right to receive or retain such consideration becomes unconditional, at which point financial instruments guidance may apply. The effective date for the standard is for fiscal years beginning after December 15, 2026 and interim periods within those fiscal years. Early adoption is permitted. The amendments in ASU 2025-07 should be applied either prospectively or by utilizing a modified retrospective approach. The Company is currently assessing the impact on the Company’s condensed consolidated financial statements and disclosures. In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. This update clarifies interim disclosure requirements and centralizes such requirements within Topic 270. Among other changes, ASU 2025-11 introduces a disclosure principle requiring entities to provide information about significant events or changes since the end of the last annual reporting period that have a material impact, clarifies when duplicative annual disclosures may be omitted from interim reports, and aligns interim reporting requirements with applicable SEC guidance for registrants. This guidance is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The amendments in ASU 2025-11 should be applied prospectively. The Company is currently assessing the impact on the Company’s condensed consolidated financial statements and disclosures. In December 2025, the FASB issued ASU 2025-12, Codification Improvements. This update addresses shareholder suggestions on the Accounting Standards Codification and makes other incremental improvements to U.S. GAAP. The amendments make codification updates to a broad range of topics arising from technical corrections, unintended application of the codification, clarifications and other minor improvements. This guidance is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods within those annual periods. Early adoption is permitted and may be elected on an issue-by-issue basis. The amendments in ASU 2025-12 are to be applied prospectively. The Company is currently assessing the impact on the Company’s condensed consolidated financial statements and disclosures.

Note 3 - Asset Acquisition Stella Diagnostics - Asset Purchase Agreement On December 15, 2022, the Company entered into an Asset Purchase Agreement (the “Stella Purchase Agreement”), with Stella Diagnostics Inc. (“Stella”) and Stella DX, LLC (“Stella DX” and, together with Stella, the “Stella Sellers”), pursuant to which, on January 3, 2023, the Company purchased all of the assets, rights and interests of the Stella Sellers and their affiliates pertaining to the Stella Sellers’ BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test and certain clinical assets, including all intellectual property rights (the “Stella Purchased Assets”). As consideration for the Stella Purchased Assets, at closing, the Company (i) paid to the Stella Sellers $3.5 million in cash, minus (a) the secured note Amount of $0.5 million, (b) the Liability Payoff Amount of $1.6 million and (c) the Promissory Note Payoff Amount of $0.4 million, and (ii) issued to Stella DX <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pid_c20230103__20230103__us-gaap--AssetAcquisitionAxis__custom--StellaPurchaseAgreementMember_zNf4LjOrgiQ2" title="Stock issued during period">10,000 shares of common stock, par value $0.0005 per share, of the Company at a value of $100.00 per share. Total consideration paid was $4.6 million. The Secured Note Amount of $0.5 million and the Promissory Note Payoff of $0.4 million were paid in 2022. The balance of the consideration was paid at closing on January 3, 2023. In addition to the consideration paid at closing, the Company will issue shares of common stock valued at $2.0 million (the “Milestone Stock”) to the Stella Sellers upon a Commercialization Event (as defined in the Stella Purchase Agreement). The Milestone stock was recorded at closing as a non-current liability at its fair value of $2.0 million. Also, the Company is required to pay to the Stella Sellers for each of the seven calendar years during the seven year period commencing on the first day of the calendar year following the date of the Commercialization Event, a non-refundable, non-creditable royalty of 5% of the Adjusted Gross Margin for such Annual Period. As of March 31, 2026, the Commercialization Event had not occurred. The asset purchase does not qualify as a business combination under FASB ASC 805, Business Combinations, and has therefore been accounted for as an asset acquisition. In connection with the Stella Purchased Assets, the Company incurred $0.2 million in transaction costs, which were capitalized as part of the purchase price of the Stella Purchased Assets. The total purchase price for the Stella Purchased Assets was $<span id="xdx_90A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn5n6_c20230103__20230103__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TechnologyBasedIntangibleAssetsMember_z4VoORbCb9h7" title="Purchase price">6.8 million (including the value of the stock to be issued upon the Commercialization Event), which was allocated to the proprietary technology intangible asset acquired. The Company is amortizing the acquired intangible asset on a straight-line basis over its estimated useful life of <span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dc_c20230103__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TechnologyBasedIntangibleAssetsMember_zloB4jcfIix" title="Finite-lived intangible asset, useful life">five years.

3500000

500000

1600000 400000

10000

0.0005

100.00

4600000

500000

400000

2000000.0

P7Y

0.05 200000

6800000

P5Y

Note 4 - Intangible Assets, Net <p id="xdx_892_eus-gaap--ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_zVZWrijNO3Ni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Intangible assets as of March 31, 2026 and December 31, 2025 consisted of the following (in thousands): Schedule of Intangible Assets <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260331_zR6sZKdptRC4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20251231_zumzIhX4L9Rb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Estimated Useful Life (in years)</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zSk7Lg73kaHk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Trade names</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,550</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,550</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: center">15</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zoguPl8TqBgg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Proprietary intellectual property</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,064</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,064</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zha56eZnx6T9" title="Estimated Useful Life (in years)">5</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zUjoU7agMw77" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,180</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,180</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z1FrUZS0eEQ7" title="Estimated Useful Life (in years)">1</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CLIALicenseMember_zN8eYbqKwUY8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">CLIA license</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: center"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CLIALicenseMember_zC0uNdP6BAYc" title="Estimated Useful Life (in years)">3</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_maFLIANzbaw_zUyQaVMdNqAg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total intangible assets, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,794</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,794</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_msFLIANzbaw_zqtZomAtc6Cl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(11,272</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(10,627</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzbaw_ziC8AnVyU3re" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total intangible assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,522</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,167</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> ProPhase Labs, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (unaudited) Amortization expense for acquired intangible assets was $0.6 million and $0.6 million during the three months ended March 31, 2026 and 2025, respectively. The estimated future amortization expense of acquired intangible assets as of March 31, 2026 is as follows (in thousands): <p id="xdx_89E_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zljmL6AqyJud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> Schedule Estimated Future Amortization Expense of Acquired Intangible Assets <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20260331_zmSE4MfxjoBa" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzwP6_zWgodvTCZ9Ca" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Remaining periods in 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,605</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzwP6_zhPq4ABZIeQa" style="vertical-align: bottom; background-color: White"> <td>Year ended December 31, 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,731</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzwP6_zbosiKKQ6yAb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year ended December 31, 2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">370</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzwP6_zJE1woUVIfde" style="vertical-align: bottom; background-color: White"> <td>Year ended December 31, 2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">370</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzwP6_zQDiXfzfysw4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year ended December 31, 2030</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">370</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_pn3n3_maFLIANzwP6_zTWCWlirlj66" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,076</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzwP6_zSCxSrBL6Q08" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total intangible assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,522</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<p id="xdx_892_eus-gaap--ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_zVZWrijNO3Ni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Intangible assets as of March 31, 2026 and December 31, 2025 consisted of the following (in thousands): Schedule of Intangible Assets <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260331_zR6sZKdptRC4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20251231_zumzIhX4L9Rb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Estimated Useful Life (in years)</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zSk7Lg73kaHk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Trade names</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,550</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,550</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: center">15</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zoguPl8TqBgg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Proprietary intellectual property</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,064</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,064</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zha56eZnx6T9" title="Estimated Useful Life (in years)">5</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zUjoU7agMw77" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,180</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,180</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z1FrUZS0eEQ7" title="Estimated Useful Life (in years)">1</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CLIALicenseMember_zN8eYbqKwUY8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">CLIA license</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: center"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CLIALicenseMember_zC0uNdP6BAYc" title="Estimated Useful Life (in years)">3</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_maFLIANzbaw_zUyQaVMdNqAg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total intangible assets, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,794</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,794</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_msFLIANzbaw_zqtZomAtc6Cl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(11,272</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(10,627</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzbaw_ziC8AnVyU3re" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total intangible assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,522</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,167</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

5550000

P15Y

11064000

P5Y

1180000

P1Y

P3Y

17794000

11272000

10627000

6522000

7167000

600000

<p id="xdx_89E_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zljmL6AqyJud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> Schedule Estimated Future Amortization Expense of Acquired Intangible Assets <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20260331_zmSE4MfxjoBa" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzwP6_zWgodvTCZ9Ca" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Remaining periods in 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,605</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzwP6_zhPq4ABZIeQa" style="vertical-align: bottom; background-color: White"> <td>Year ended December 31, 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,731</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzwP6_zbosiKKQ6yAb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year ended December 31, 2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">370</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzwP6_zJE1woUVIfde" style="vertical-align: bottom; background-color: White"> <td>Year ended December 31, 2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">370</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzwP6_zQDiXfzfysw4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year ended December 31, 2030</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">370</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_pn3n3_maFLIANzwP6_zTWCWlirlj66" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,076</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzwP6_zSCxSrBL6Q08" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total intangible assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,522</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1605000

1731000

370000

2076000

6522000

Note 5 - Outstanding Debt 2026 Convertible Notes On January 13, 2026, the Company entered into a securities purchase agreement (the “Agreement”) with an individual investor (the “Holder”) providing for the issuance of a <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20260113__us-gaap--DebtInstrumentAxis__custom--NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_z9CncFkLVmgl" title="Interest rate">10% convertible promissory note (the “Note”) in the principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20260113__us-gaap--DebtInstrumentAxis__custom--NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_z8lchNGUAudi" title="Aggregate principal amount">240,000. The Convertible Note permits the Holder to convert outstanding principal and accrued interest into shares of common stock at a conversion price that is <span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_c20260113__20260113__us-gaap--DebtInstrumentAxis__custom--NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_zJz0yhINXj3d" title="Debt instrument, convertible, threshold percentage of stock price trigger">75% of the trailing <span id="xdx_902_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_dc_uInteger_c20260113__20260113__us-gaap--DebtInstrumentAxis__custom--NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_zf6iQL64eZ65" title="Debt instrument, convertible, threshold trading days">five-day volume weighted average price (“VWAP”) immediately preceding the respective conversion date. The Company received cash proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromShortTermDebt_c20260113__20260113__us-gaap--DebtInstrumentAxis__custom--NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_zC8D8z0kRv69" title="Proceeds from short-term debt">190,000, which is net of original issue discount of $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20260113__us-gaap--DebtInstrumentAxis__custom--NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_zMz0TurzMCU1" title="Discount, current">40,000 and issuance cost of $<span id="xdx_907_eus-gaap--DeferredFinanceCostsGross_iI_c20260113__us-gaap--DebtInstrumentAxis__custom--NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_zDivVpr9ITo1" title="Debt issuance costs">10,000. The Note has a maturity date on January 13, 2027. Total payments of $<span id="xdx_90A_eus-gaap--DebtInstrumentPeriodicPayment_c20260113__20260113__us-gaap--DebtInstrumentAxis__custom--NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_zPmElNIwMBH2" title="Periodic payment">264,000 will be made in <span id="xdx_90B_ecustom--DebtInstrumentNumberOfPeriodicPayments_dc_uInteger_c20260113__20260113__us-gaap--DebtInstrumentAxis__custom--NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_zTMoeSNk1Yca" title="Number of periodic payments">four monthly installment payments, which won’t be started until July 13, 2026 in accordance with the payment schedule pursuant to the note agreement. In consideration for entering into the Agreement, the Company also issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260113__20260113__us-gaap--DebtInstrumentAxis__custom--NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_zjZJlEqKY0Ja" title="Stock Issued During Period, Shares, New Issues">80,000 shares of common stock to the Investor in connection with the Note. On January 27, 2026 (the “Issue Date”), the Company entered into a securities purchase agreement (the “January Labrys SPA”) with Labrys Fund II, LP (“Labrys”), pursuant to which the Company issued a <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20260127__us-gaap--DebtInstrumentAxis__custom--JanuaryLabrysNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_zMsr9Ll612Y" title="Interest rate">10% promissory note (the “January Labrys Note”) with a maturity date of January 27, 2027, in the principal sum of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20260127__us-gaap--DebtInstrumentAxis__custom--JanuaryLabrysNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_zd7QCfunxHe6" title="Aggregate principal amount">180,000. The Company received cash proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromShortTermDebt_c20260127__20260127__us-gaap--DebtInstrumentAxis__custom--JanuaryLabrysNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_ze0KflniY0m1" title="Proceeds from short-term debt">140,000, which is net of original issue discount of $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20260127__us-gaap--DebtInstrumentAxis__custom--JanuaryLabrysNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_ztkrT1Qihnm" title="Discount, current">30,000 and issuance cost of $<span id="xdx_905_eus-gaap--DeferredFinanceCostsGross_iI_c20260127__us-gaap--DebtInstrumentAxis__custom--JanuaryLabrysNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_zYjbGOx9y4dg" title="Debt issuance costs">10,000. In addition, the Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260127__20260127__us-gaap--DebtInstrumentAxis__custom--JanuaryLabrysNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_zxsr2EHx6NIi" title="Stock Issued During Period, Shares, New Issues">75,000 shares of its common stock to Labrys as a commitment fee pursuant to the January Labrys SPA. The January Labrys Note is convertible into the Company’s common stock (subject to the beneficial ownership limitations of <span id="xdx_90D_ecustom--DebtInstrumentConvertibleBeneficialOwnershipLimitationPercentage_iI_pid_dp_c20260127__us-gaap--DebtInstrumentAxis__custom--JanuaryLabrysNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable__us-gaap--InvestmentTypeAxis__custom--JanuaryLabrysSPAMember_zKDCG4jsnGN4" title="Debt instrument, convertible, beneficial ownership limitation, percentage">4.99% in the January Labrys Note) after <span id="xdx_901_ecustom--DebtInstrumentConvertiblePeriodFromIssuanceDate_iI_dtD_uInteger_c20260127__us-gaap--DebtInstrumentAxis__custom--JanuaryLabrysNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_zjxvaNb1Z5q3" title="Debt instrument, convertible, period from issuance date">180 days after the Issue Date at a conversion price at <span id="xdx_907_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_c20260127__20260127__us-gaap--DebtInstrumentAxis__custom--JanuaryLabrysNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_zhj7wgvDgMea" title="Debt instrument, convertible, threshold percentage of stock price trigger">80% of the lowest traded price over the <span id="xdx_908_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_dc_uInteger_c20260127__20260127__us-gaap--DebtInstrumentAxis__custom--JanuaryLabrysNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_zx5SRUOlrQI" title="Debt instrument, convertible, threshold trading days">ten prior trading days immediately preceding the respective conversion date. On March 10, 2026 (the “Issue Date”), the Company entered into another securities purchase agreement (the “March Labrys SPA”) with Labrys, pursuant to which the Company issued a <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20260310__us-gaap--DebtInstrumentAxis__custom--MarchLabrysNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_zBw3oC2Igkuk" title="Interest rate">10% promissory note (the “March Labrys Note”) with a maturity date of March 10, 2027, in the principal sum of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20260310__us-gaap--DebtInstrumentAxis__custom--MarchLabrysNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_zCHDmBtGExwa" title="Aggregate principal amount">78,000. The Company received cash proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromShortTermDebt_c20260310__20260310__us-gaap--DebtInstrumentAxis__custom--MarchLabrysNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_zEiVuOCWmsFc" title="Proceeds from short-term debt">55,000, which is net of original issue discount of $<span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20260310__us-gaap--DebtInstrumentAxis__custom--JanuaryLabrysNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_zsyDkvZbCGF" title="Discount, current">13,000 and issuance cost of $<span id="xdx_909_eus-gaap--DeferredFinanceCostsGross_iI_c20260310__us-gaap--DebtInstrumentAxis__custom--MarchLabrysNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_zAJIZDRDvjN7" title="Debt issuance costs">10,000. The March Labrys Note is convertible into the Company’s common stock (subject to the beneficial ownership limitations of <span id="xdx_90F_ecustom--DebtInstrumentConvertibleBeneficialOwnershipLimitationPercentage_iI_pid_dp_c20260310__us-gaap--DebtInstrumentAxis__custom--MarchLabrysNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable__us-gaap--InvestmentTypeAxis__custom--MarchLabrysSPAMember_zW1afx8RJjGb" title="Debt instrument, convertible, beneficial ownership limitation, percentage">4.99% in the March Labrys Note) after <span id="xdx_90E_ecustom--DebtInstrumentConvertiblePeriodFromIssuanceDate_iI_dtD_uInteger_c20260310__us-gaap--DebtInstrumentAxis__custom--MarchLabrysNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_zJ1N2EJ4I31c" title="Debt instrument, convertible, period from issuance date">180 days after the Issue Date at a conversion price at <span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_c20260310__20260310__us-gaap--DebtInstrumentAxis__custom--MarchLabrysNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_zYljUAAY8oLe" title="Debt instrument, convertible, threshold percentage of stock price trigger">80% of the lowest traded price over the <span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_dc_uInteger_c20260310__20260310__us-gaap--DebtInstrumentAxis__custom--MarchLabrysNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayable_zpxMEAmJ0px2" title="Debt instrument, convertible, threshold trading days">ten prior trading days immediately preceding the respective conversion date. The conversion option of the 2026 Convertible Notes contains variable conversion price, which fails the equity classification guidance in ASC 815 and is thus precluded from being classified in equity. Therefore, the embedded derivatives are required to be bifurcated from the 2026 Convertible Notes and accounted for at fair value at each reporting date. A fair value of $<span id="xdx_90E_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_iI_c20260310__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zTy8N8tqkLS2" title="Embedded derivative, fair value of embedded derivative liability">308,000 was determined for the embedded derivative liabilities on the issuance date. The embedded derivative liabilities will be re-measured to fair value each reporting period until settlement (see Note 15). March 2026 Future Receipts Financing Agreements On March 17, 2026, the Company entered into an agreement of sale of future receipts (“First 2026 Future Receipts Financing Agreement”) with Legendary Funding Group, LLC (“Legendary”) by which Legendary purchased from the Company, its future accounts and contract rights arising from the sale of goods or rendition of services to the Company’s customers. The purchase price was $<span id="xdx_900_eus-gaap--ProceedsFromNotesPayable_c20260317__20260317__us-gaap--DebtInstrumentAxis__custom--FirstTwentyTwentySixFutureReceiptsFinancingAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayable_z5jVN4WHZDW4" title="Proceeds from issuance of note payable">80,000, which was paid to the Company on March 18, 2026, net of a $<span id="xdx_908_eus-gaap--DebtInstrumentFeeAmount_iI_c20260317__us-gaap--DebtInstrumentAxis__custom--FirstTwentyTwentySixFutureReceiptsFinancingAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayable_zIUO5m8YYbLk" title="Origination fee">3,450 origination fee. The Company also incurred a $<span id="xdx_903_ecustom--DebtInstrumentBrokerageFees_c20260317__20260317__us-gaap--DebtInstrumentAxis__custom--FirstTwentyTwentySixFutureReceiptsFinancingAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayable_zP5gOkDpLtc3" title="Brokerage fee">36,000 brokerage fee. The First 2026 Future Receipts Financing Agreement requires <span id="xdx_906_ecustom--DebtInstrumentNumberOfPeriodicPayments_dc_uInteger_c20260317__20260317__us-gaap--DebtInstrumentAxis__custom--FirstTwentyTwentySixFutureReceiptsFinancingAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayable_zzRZvTY4W2Xa" title="Number of periodic payments">eighteen weekly payments of $<span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_c20260317__20260317__us-gaap--DebtInstrumentAxis__custom--FirstTwentyTwentySixFutureReceiptsFinancingAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayable_z5AhLax6LIwk" title="Periodic payment">6,444 for a total repayment of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20260317__us-gaap--DebtInstrumentAxis__custom--FirstTwentyTwentySixFutureReceiptsFinancingAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayable_z1MwAlu5JNX2" title="Aggregate principal amount">116,000 over the term of the agreement. As of March 31, 2026, the outstanding balance under the First 2026 Future Financing Agreement was approximately $<span id="xdx_900_ecustom--DebtInstrumentOutstandingBalance_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--FirstTwentyTwentySixFutureReceiptsFinancingAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayable_zGocazc2CAIh" title="Outstanding balance">70,000, net of $<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--FirstTwentyTwentySixFutureReceiptsFinancingAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayable_zfTBvtoYIle7" title="Unamortized debt discount">33,000 unamortized debt discount. On March 17, 2026, the Company entered into an agreement of sale of future receipts (“Second 2026 Future Receipts Financing Agreement”) with Immediate Capital Solutions LLC (“Immediate Advances”) by which Immediate Advances purchased from the Company, its future accounts and contract rights arising from the sale of goods or rendition of services to the Company’s customers. The purchase price was $<span id="xdx_906_eus-gaap--ProceedsFromNotesPayable_c20260317__20260317__us-gaap--DebtInstrumentAxis__custom--SecondTwentyTwentySixFutureReceiptsFinancingAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayable_zYqVD8K7XO3l" title="Proceeds from issuance of note payable">220,000, which was paid to the Company on March 18, 2026, net of a $<span id="xdx_90A_eus-gaap--DebtInstrumentFeeAmount_iI_c20260317__us-gaap--DebtInstrumentAxis__custom--SecondTwentyTwentySixFutureReceiptsFinancingAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayable_zAdxdBv4SG2l" title="Origination fee">8,800 origination fee. The Company also incurred a $<span id="xdx_90B_ecustom--DebtInstrumentBrokerageFees_c20260317__20260317__us-gaap--DebtInstrumentAxis__custom--SecondTwentyTwentySixFutureReceiptsFinancingAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayable_zJY7yMRCD0d1" title="Brokerage fee">69,000 brokerage fee. The Second 2026 Future Receipts Financing Agreement requires <span id="xdx_90F_ecustom--DebtInstrumentNumberOfPeriodicPayments_uInteger_c20260317__20260317__us-gaap--DebtInstrumentAxis__custom--SecondTwentyTwentySixFutureReceiptsFinancingAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayable_zwkC89JBjKfi" style="display: none" title="Number of periodic payments">25twenty-five weekly payments of approximately $<span id="xdx_903_eus-gaap--DebtInstrumentPeriodicPayment_c20260317__20260317__us-gaap--DebtInstrumentAxis__custom--SecondTwentyTwentySixFutureReceiptsFinancingAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayable_zIVQ2HVRQmpc" title="Periodic payment">11,000 for a total repayment of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20260317__us-gaap--DebtInstrumentAxis__custom--SecondTwentyTwentySixFutureReceiptsFinancingAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayable_zRbPzqN08ff2" title="Aggregate principal amount">289,000 over the term of the agreement. As of March 31, 2026, the outstanding balance under the Second 2026 Future Financing Agreement was approximately $<span id="xdx_900_ecustom--DebtInstrumentOutstandingBalance_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--SecondTwentyTwentySixFutureReceiptsFinancingAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayable_zSsUSjMUJImi" title="Outstanding balance">209,000, net of $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--SecondTwentyTwentySixFutureReceiptsFinancingAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayable_zDtQAg7wsAS4" title="Unamortized debt discount">68,000 unamortized debt discount. 2025 Loan Agreements with Warrants On June 22, 2025, the Company entered into <span id="xdx_906_ecustom--DebtInstrumentNumberOfNonConvertiblePromissoryNotesIssued_iI_uInteger_c20250622__us-gaap--DebtInstrumentAxis__custom--NonConvertiblePromissoryNotesMember_z0s5OMN0X8vl" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 11pt" title="Debt instrument number of non convertible promissory notes issued">2two identical loan agreements with Ted Karkus, the Company’s Chief Executive Officer and the Chairman of the Board of Directors (the “CEO Loan”), and an unaffiliated investor (the “Unaffiliated Investor Loan”), pursuant to which the Company issued <span id="xdx_900_ecustom--DebtInstrumentNumberOfNonConvertiblePromissoryNotesIssued_iI_dc_uInteger_c20250622__us-gaap--DebtInstrumentAxis__custom--NonConvertiblePromissoryNotesMember_zEKh4VwWbPzd" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 11pt" title="Debt instrument number of non convertible promissory notes issued">2two 12 twelve-month non- convertible promissory notes in the principal amount of $625,000 each. Both loans included an original issuance discount of $125,000 and bear an annual interest rate of 10%. The Company received net cash proceeds of $500,000 from the CEO Loan. In connection with the issuance of the CEO Loan, the Company also issued <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250622__us-gaap--DebtInstrumentAxis__custom--CEOLoanMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CEOWarrantsMember_zUvPPiSeuD2d" title="Unvested warrants">50,000 warrants (the “CEO Warrants”), which vested upon the approval by the Company’s stockholders of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock (the “Certificate of Amendment”) at the special meeting of stockholders held on September 9, 2025. The CEO Warrants have an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250622__us-gaap--DebtInstrumentAxis__custom--CEOLoanMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CEOWarrantsMember_zLVtnX0pJQqk" title="Exercise price per share">6.00 for a term of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250622__us-gaap--DebtInstrumentAxis__custom--CEOLoanMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CEOWarrantsMember_zSo0Herthm7b" title="Warrants outstanding, term (in years)">5.0 years. The grant date fair value of the CEO Warrants were valued at $<span id="xdx_905_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20250622__us-gaap--DebtInstrumentAxis__custom--CEOLoanMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CEOWarrantsMember_zcbsmOX1OHa1" title="Warrant, fair value">115,000 using the Black-Scholes option pricing model with the following assumptions: <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dpo_c20250622__20250622__us-gaap--DebtInstrumentAxis__custom--CEOLoanMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CEOWarrantsMember_zZY3QvTUEd3i" title="Expected dividend yield">no dividend yield, expected volatility of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20250622__20250622__us-gaap--DebtInstrumentAxis__custom--CEOLoanMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CEOWarrantsMember_zBntdaltAWq4" title="Expected stock price volatility">98.4%, risk free interest rate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20250622__20250622__us-gaap--DebtInstrumentAxis__custom--CEOLoanMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CEOWarrantsMember_zXNW7qpUH197" title="Risk-free rate of interest">4.0% and expected warrant life of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250622__20250622__us-gaap--DebtInstrumentAxis__custom--CEOLoanMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CEOWarrantsMember_zsdx61JYvm7c" title="Expected term (in years)">5.0 years. The fair value of the CEO Warrants was recorded as an additional debt discount to the note payable. ProPhase Labs, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (unaudited) The Unaffiliated Investor Loan was issued as an exchange to a term note issued in 2024. No additional cash proceeds were provided. The Company accounted for the issuance of the Unaffiliated Investor Loan as an extinguishment of the original debt of $500,000 and the recognition of new debt which is initially measured at its fair value of $433,000. In connection with the issuance of the Unaffiliated Investor Loan, the Company also issued <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250622__us-gaap--DebtInstrumentAxis__custom--UnaffiliatedInvestorLoanMember__us-gaap--ClassOfWarrantOrRightAxis__custom--UnaffiliatedInvestorWarrantsMember_zacfhj0WDEH1" title="Unvested warrants (in shares)">50,000 unvested warrants (the “Unaffiliated Investor Warrants”) to the Unaffiliated Investor. The Unaffiliated Investor Warrants contain the same terms as the CEO Warrants. Accordingly, the Unaffiliated Investor Warrants have a fair value of $<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20250622__us-gaap--DebtInstrumentAxis__custom--UnaffiliatedInvestorLoanMember__us-gaap--ClassOfWarrantOrRightAxis__custom--UnaffiliatedInvestorWarrantsMember_zY8cR5NE7TRk" title="Warrant, fair value">115,000 on the issuance date. 2025 Short-term Loans On August 1, 2025, the Company entered into a note agreement with an individual investor (the “Holder”) for cash proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromShortTermDebt_pp0p0_c20250801__20250801__us-gaap--DebtInstrumentAxis__custom--FirstAugust2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_znAaUUnkidG3" title="Proceeds from short-term debt">100,000 (the “First August 2025 Note”), which is net of an original issue discount of $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_pp0p0_c20250801__us-gaap--DebtInstrumentAxis__custom--FirstAugust2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zUrvh6zvVdQ2" title="Discount, current">15,000. The First August 2025 Note is due on May 30, 2026. Total payments of $<span id="xdx_903_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20250801__20250801__us-gaap--DebtInstrumentAxis__custom--FirstAugust2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zcBzlZjJtOQh" title="Periodic payment">126,750 will be made in <span id="xdx_90D_ecustom--DebtInstrumentNumberOfPeriodicPayments_dc_uInteger_c20250801__20250801__us-gaap--DebtInstrumentAxis__custom--FirstAugust2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zGx4VTta0xz4" title="Number of periodic payments">four monthly installment payments effective on January 30, 2026 in accordance with the payment schedule pursuant to the note agreement. During the three months ended March 31, 2026, the Company recognized $<span id="xdx_908_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20250801__20250801__us-gaap--DebtInstrumentAxis__custom--FirstAugust2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zwsktWX8RbM6" title="Amortization of debt discount">3,000 interest expense from the amortization of debt discount using the effective interest rate method on the condensed consolidated statement of operations. On January 23, 2026, the Company and the Holder entered into an amendment (the “Amended First August 2025 Note”), pursuant to which at the Holder’s option, the First August 2025 Note is convertible into the Company’s common stock at a conversion price at <span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pp0p0_c20260123__us-gaap--DebtInstrumentAxis__custom--FirstAugust2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zK8mh4mUS0Ea" title="Conversion price">65% of the lowest traded price over the ten prior trading days immediately preceding the respective conversion date. The amendment was accounted as a debt extinguishment. The optional redemption includes an exercise contingency, which fails the equity classification guidance in ASC 815 and is thus precluded from being classified in equity. Therefore, the embedded derivatives are required to be bifurcated from the Amended First August 2025 Note and accounted for at fair value at each reporting date. A fair value of $<span id="xdx_90C_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_iI_pp0p0_c20260123__us-gaap--DebtInstrumentAxis__custom--FirstAugust2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_z2HoECIHSBqi" title="Embedded derivative, fair value of embedded derivative liability">129,000 was determined for the embedded derivative liabilities. The embedded derivative liabilities will be re-measured to fair value each reporting period until settlement (see Note 15). The Company recognized approximately $<span id="xdx_908_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0p0_c20260123__20260123__us-gaap--DebtInstrumentAxis__custom--FirstAugust2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zC8tFsjbO3Ba" title="Debt extinguishment loss">126,000 debt extinguishment loss as of the amendment date. During the three months ended March 31, 2026, the Holder converted $<span id="xdx_90E_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--FirstAugust2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zvkqbT4UTgj7" title="Convertible note">62,000 of the Amended First August 2025 Note into <span id="xdx_901_eus-gaap--SharesIssued_iI_pp0p0_c20260331__us-gaap--DebtInstrumentAxis__custom--FirstAugust2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zVz9rsRX38V7" title="Shares of common stock">813,362 shares of the Company’s common stock. The aggregate fair value of the common stock issued on the conversion date was approximately $<span id="xdx_90D_eus-gaap--ConvertibleNotesPayableCurrent_iI_pp0p0_c20260331__us-gaap--DebtInstrumentAxis__custom--FirstAugust2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zSvYEjIsZdx7" title="Fair value of convertible note">113,000. The Company also extinguished approximately $<span id="xdx_905_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_iI_pp0p0_c20260331__us-gaap--DebtInstrumentAxis__custom--FirstAugust2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z3yIJPUkTOOl" title="Embedded derivative, fair value of embedded derivative liability">51,000 embedded derivative liability upon the conversion. On August 14, 2025, the Company entered into a note agreement with an individual investor for cash proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromShortTermDebt_pp0p0_c20250814__20250814__us-gaap--DebtInstrumentAxis__custom--SecondAugust2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_z6CcDdNEGDZb" title="Proceeds from short-term debt">150,000 (the “Second August 2025 Note”). The Second August 2025 Note is due on August 14, 2026 and requires the Company to make interest only quarterly payments in the amount of $<span id="xdx_900_eus-gaap--DebtInstrumentPeriodicPaymentInterest_pp0p0_c20250814__20250814__us-gaap--DebtInstrumentAxis__custom--SecondAugust2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zr6TPAArQZ4j" title="Periodic payment interest">9,452 with a $<span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_iI_pp0p0_c20250814__us-gaap--DebtInstrumentAxis__custom--SecondAugust2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zyEn9yvKcSu5" title="Debt instrument, periodic payment terms, balloon payment to be paid">159,452 balloon payment at the end of the term. On August 1, 2025 and September 11, 2025, the Company entered into <span id="xdx_90F_ecustom--DebtInstrumentNumberOfAgreementsEnteredInto_iI_dc_uInteger_c20250911__us-gaap--DebtInstrumentAxis__custom--ThirdAugust2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zbQimT5SSyt1" title="Debt instrument, number of agreements entered into agreement">two note agreements (collectively the “Third August 2025 Notes”) with same individual investor (the “Lender”) for an aggregate cash proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromShortTermDebt_pp0p0_c20250801__20250911__us-gaap--DebtInstrumentAxis__custom--ThirdAugust2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zzNHxyGsT95e" title="Proceeds from short-term debt">400,000, which is net of original issue discount and issuance cost of $<span id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_pp0p0_c20250911__us-gaap--DebtInstrumentAxis__custom--ThirdAugust2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zfgsoUrHYsO7" title="Debt instrument, unamortized discount (premium) and debt issuance costs, net">76,000. The Third August 2025 Notes has a <span id="xdx_90B_eus-gaap--DebtInstrumentTerm_dtY_c20250801__20250911__us-gaap--DebtInstrumentAxis__custom--ThirdAugust2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zCMFTlEkQyJf" title="Term note period (in years)">10 months term. Total payments of $<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20250801__20250911__us-gaap--DebtInstrumentAxis__custom--ThirdAugust2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zPIn4RgnOoil" title="Periodic payment">528,000 will be made in <span id="xdx_90D_ecustom--DebtInstrumentNumberOfPeriodicPayments_dc_uInteger_c20250801__20250911__us-gaap--DebtInstrumentAxis__custom--ThirdAugust2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zeefeS7qQ8x8" title="Number of periodic payments">four monthly installment payments, which won’t be started until <span id="xdx_906_ecustom--DebtInstrumentPeriodicPaymentDelayFromIssuanceDatePeriod_dtM_c20250801__20250911__us-gaap--DebtInstrumentAxis__custom--ThirdAugust2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zfx3xBzNOW2e" title="Debt instrument, periodic payment delay from issuance date, period">6 months from the issuance date in accordance with the payment schedule pursuant to the note agreements. During the three months ended March 31, 2026, the Company recognized $<span id="xdx_90A_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--ThirdAugust2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zaVjf2uATiYk" title="Amortization of debt discount">18,000 interest expense from the amortization of debt discount using the effective interest rate method on the condensed consolidated statement of operations. On January 23, 2026, the Company and the Lender entered into an amendment to amend the note that was issued on August 1, 2025 (the “Amended Note”) with principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20260123__us-gaap--DebtInstrumentAxis__custom--ThirdAugust2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zBIWD8Q4SJY4" title="Principal amount">238,000, pursuant to which at the Lender’s option, the Amended Note is convertible into the Company’s common stock at a conversion price at <span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pp0p0_c20260123__us-gaap--DebtInstrumentAxis__custom--ThirdAugust2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zI8aXCMOFXD" title="Conversion price">65% of the lowest traded price over the ten prior trading days immediately preceding the respective conversion date. The amendment was accounted as a debt extinguishment. The optional redemption includes an exercise contingency, which fails the equity classification guidance in ASC 815 and is thus precluded from being classified in equity. Therefore, the embedded derivatives are required to be bifurcated from the Amended August Note and accounted for at fair value at each reporting date. A fair value of $<span id="xdx_906_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_iI_pp0p0_c20260123__us-gaap--DebtInstrumentAxis__custom--ThirdAugust2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zydWi8iiXzm4" title="Embedded derivative, fair value of embedded derivative liability">289,000 was determined for the embedded derivative liabilities. The embedded derivative liabilities will be re-measured to fair value each reporting period until settlement (see Note 15). The Company recognized approximately $<span id="xdx_900_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0p0_c20260123__20260123__us-gaap--DebtInstrumentAxis__custom--ThirdAugust2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zwLxx7cHpiic" title="Debt extinguishment loss">287,000 debt extinguishment loss as of the amendment date. During the three months ended March 31, 2026, the Lender converted $<span id="xdx_907_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--ThirdAugust2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zXexft7tzcOb" title="Convertible note">85,000 of the Amended August Note into <span id="xdx_904_eus-gaap--SharesIssued_iI_pp0p0_c20260331__us-gaap--DebtInstrumentAxis__custom--ThirdAugust2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zVGXdkrAMyT3" title="Shares of common stock">1,010,875 shares of the Company’s common stock. The aggregate fair value of the common stock issued on the conversion date was approximately $<span id="xdx_904_eus-gaap--ConvertibleNotesPayableCurrent_iI_pp0p0_c20260331__us-gaap--DebtInstrumentAxis__custom--ThirdAugust2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zS6c96je0LS5" title="Fair value of convertible note">144,000. The Company also extinguished approximately $<span id="xdx_90E_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_iI_pp0p0_c20260331__us-gaap--DebtInstrumentAxis__custom--ThirdAugust2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zcDC572isfUi" title="Embedded derivative, fair value of embedded derivative liability">59,000 embedded derivative liability upon the conversion. On November 6, 2025, the Company entered into a note agreement ( the “November 2025 Note”) with an individual investor for an aggregate cash proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromShortTermDebt_pp0p0_c20251106__20251106__us-gaap--DebtInstrumentAxis__custom--November2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_z1Y36ly5RCxh" title="Proceeds from short-term debt">135,000, which is net of original issue discount and issuance cost of $<span id="xdx_901_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_pp0p0_c20251106__us-gaap--DebtInstrumentAxis__custom--November2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zovJyoR4UV6j" title="Debt instrument, unamortized discount (premium) and debt issuance costs, net">28,000. The November 2025 Notes has a <span id="xdx_90B_eus-gaap--DebtInstrumentTerm_dtY_c20251106__20251106__us-gaap--DebtInstrumentAxis__custom--November2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zd6VNjiTgzj3" title="Term note period (in years)">10 months term. Total payments of $<span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20251106__20251106__us-gaap--DebtInstrumentAxis__custom--November2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zT7bg0FeiYib" title="Periodic payment">181,000 will be made in <span id="xdx_90E_ecustom--DebtInstrumentNumberOfPeriodicPayments_dc_uInteger_c20251106__20251106__us-gaap--DebtInstrumentAxis__custom--November2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_z2DjfsBjqD6k" title="Number of periodic payments">four monthly installment payments, which won’t be started until <span id="xdx_909_ecustom--DebtInstrumentPeriodicPaymentDelayFromIssuanceDatePeriod_dtM_c20251106__20251106__us-gaap--DebtInstrumentAxis__custom--November2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zCMVXPJBq4Vc" title="Debt instrument, periodic payment delay from issuance date, period">6 months from the issuance date in accordance with the payment schedule pursuant to the note agreements. During the three months ended March 31, 2026, the Company recognized $<span id="xdx_90F_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--November2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_z4gh7DlzxQqh" title="Amortization of debt discount">12,000 interest expense from the amortization of debt discount using the effective interest rate method on the condensed consolidated statement of operations. On December 22, 2025, the Company entered into a note agreement ( the “First December 2025 Note”) with an individual investor for an aggregate cash proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromShortTermDebt_pp0p0_c20251222__20251222__us-gaap--DebtInstrumentAxis__custom--FirstDecember2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zAUu9SC1qsbi" title="Proceeds from short-term debt">50,000, which is net of original issue discount and issuance cost of $<span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_pp0p0_c20251222__us-gaap--DebtInstrumentAxis__custom--FirstDecember2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zBPs79WTXic5" title="Debt instrument, unamortized discount (premium) and debt issuance costs, net">8,000. The First December 2025 Notes has a <span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20251222__20251222__us-gaap--DebtInstrumentAxis__custom--FirstDecember2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zQtHtsSKVfdh" title="Term note period (in years)">10 months term. Total payments of $<span id="xdx_900_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20251222__20251222__us-gaap--DebtInstrumentAxis__custom--FirstDecember2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zNYqqIbxc192" title="Periodic payment">64,000 will be made in <span id="xdx_906_ecustom--DebtInstrumentNumberOfPeriodicPayments_dc_uInteger_c20251222__20251222__us-gaap--DebtInstrumentAxis__custom--FirstDecember2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_z7b7Ezxu8Vp6" title="Number of periodic payments">four monthly installment payments, which won’t be started until <span id="xdx_907_ecustom--DebtInstrumentPeriodicPaymentDelayFromIssuanceDatePeriod_dtM_c20251222__20251222__us-gaap--DebtInstrumentAxis__custom--FirstDecember2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_z5ZFvgGJ2btc" title="Debt instrument, periodic payment delay from issuance date, period">6 months from the issuance date in accordance with the payment schedule pursuant to the note agreements. During the three months ended March 31, 2026, the Company recognized $<span id="xdx_905_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--FirstDecember2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zecgosa3lBH8" title="Amortization of debt discount">3,000 interest expense from the amortization of debt discount using the effective interest rate method on the condensed consolidated statement of operations. On December 26, 2025, the Company entered into a note agreement ( the “Second December 2025 Note”) with an individual investor for an aggregate cash proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromShortTermDebt_pp0p0_c20251226__20251226__us-gaap--DebtInstrumentAxis__custom--SecondDecember2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zYb7lCFVtGW2" title="Proceeds from short-term debt">75,000, which is net of original issue discount and issuance cost of $<span id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_pp0p0_c20251226__us-gaap--DebtInstrumentAxis__custom--SecondDecember2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zW3cYZa7l8Zi" title="Debt instrument, unamortized discount (premium) and debt issuance costs, net">19,000. The Second December 2025 Notes has a <span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20251226__20251226__us-gaap--DebtInstrumentAxis__custom--SecondDecember2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_z8vVh7IQFRZ1" title="Term note period (in years)">10 months term. Total payments of $<span id="xdx_901_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20251226__20251226__us-gaap--DebtInstrumentAxis__custom--SecondDecember2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zAmRUAiR4Dv" title="Periodic payment">105,000 will be made in <span id="xdx_90F_ecustom--DebtInstrumentNumberOfPeriodicPayments_dc_uInteger_c20251226__20251226__us-gaap--DebtInstrumentAxis__custom--SecondDecember2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zg5RRd7y5MXb" title="Number of periodic payments">four monthly installment payments, which won’t be started until <span id="xdx_90C_ecustom--DebtInstrumentPeriodicPaymentDelayFromIssuanceDatePeriod_dtM_c20251226__20251226__us-gaap--DebtInstrumentAxis__custom--SecondDecember2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zvc802xdHH8l" title="Debt instrument, periodic payment delay from issuance date, period">6 months from the issuance date in accordance with the payment schedule pursuant to the note agreements. During the three months ended March 31, 2026, the Company recognized $<span id="xdx_906_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--SecondDecember2025NoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_ziXlYXvOYQXd" title="Amortization of debt discount">7,000 interest expense from the amortization of debt discount using the effective interest rate method on the condensed consolidated statement of operations. August 2025 Future Receipts Financing Agreements On August 22, 2025, the Company entered into <span id="xdx_904_ecustom--DebtInstrumentNumberOfAgreementsEnteredInto_iI_dc_uInteger_c20250822__us-gaap--DebtInstrumentAxis__custom--August2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zElb7CSWdVck" title="Debt instrument, number of agreements entered into agreement">two agreements of sale of future receipts (“August Future Receipts Financing Agreements”) with Terrapin Business Funding, LLC (“Terrapin”) by which Terrapin purchased from the Company, its future accounts and contract rights arising from the sale of goods or rendition of services to the Company’s customers. The Company received net cash proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromRepaymentsOfShortTermDebt_pp0p0_c20250825__20250825__us-gaap--DebtInstrumentAxis__custom--August2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zqaNjIZr9hba" title="Net proceeds from short-term debt">700,000 on August 25, 2025, which was net of $<span id="xdx_90D_eus-gaap--DebtInstrumentFeeAmount_iI_pp0p0_c20250825__us-gaap--DebtInstrumentAxis__custom--August2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zPV4Awo0mkek" title="Origination fee">188,000 origination fee and $<span id="xdx_902_eus-gaap--RepaymentsOfShortTermDebt_pp0p0_c20250825__20250825__us-gaap--DebtInstrumentAxis__custom--LibertasFinancingAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zrjbvwXmF4k2" title="Repayments of short-term debt">553,000 distribution from the flow of funds to pay off the remaining balance pursuant to the Libertas Financing Agreement. ProPhase Labs, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (unaudited) The August Future Receipts Financing Agreements require <span id="xdx_905_ecustom--DebtInstrumentNumberOfPeriodicPayments_dc_uInteger_c20250822__20250822__us-gaap--DebtInstrumentAxis__custom--August2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zkZ7dDBNsYnj" title="Number of periodic payments">twelve monthly payments of $<span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20250822__20250822__us-gaap--DebtInstrumentAxis__custom--August2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_z8PU7ifpMUg" title="Periodic payment">120,083 for a total repayment of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20250822__us-gaap--DebtInstrumentAxis__custom--August2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_z8svNHUWlYb6" title="Aggregate principal amount">1.4 million over the term of the agreement. No payment has been made as of March 31, 2026. In connection with the issuance of the August Future Receipts Financing Agreements, the Company also issued <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250822__us-gaap--DebtInstrumentAxis__custom--August2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember__us-gaap--ClassOfWarrantOrRightAxis__custom--AugustWarrantsMember_z4RBbxvlclT3" title="Unvested warrants (in shares)">50,000 warrants (the “August Warrants”) as an additional issuance cost. The Warrants have an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250822__us-gaap--DebtInstrumentAxis__custom--August2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember__us-gaap--ClassOfWarrantOrRightAxis__custom--AugustWarrantsMember_ztluCQMDnptj" title="Exercise price per share">5.00 per share for a term of <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250822__us-gaap--DebtInstrumentAxis__custom--August2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember__us-gaap--ClassOfWarrantOrRightAxis__custom--AugustWarrantsMember_zi6N5T5hX9Ca" title="Warrants outstanding, term (in years)">5.0 years. The grant date fair value of the August Warrants were valued at $<span id="xdx_905_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20250822__us-gaap--DebtInstrumentAxis__custom--August2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember__us-gaap--ClassOfWarrantOrRightAxis__custom--AugustWarrantsMember_z37ktSW8pKr6" title="Warrant, fair value">120,000 using the Black-Scholes option pricing model with the following assumptions: <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_do_c20250822__20250822__us-gaap--DebtInstrumentAxis__custom--August2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember__us-gaap--ClassOfWarrantOrRightAxis__custom--AugustWarrantsMember_zDKg9nKYYy2" title="Expected dividend yield (per share)">no dividend yield, expected volatility of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20250822__20250822__us-gaap--DebtInstrumentAxis__custom--August2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember__us-gaap--ClassOfWarrantOrRightAxis__custom--AugustWarrantsMember_zGyvEyFLsubk" title="Expected stock price volatility (as a percent)">98.3%, risk free interest rate of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20250822__20250822__us-gaap--DebtInstrumentAxis__custom--August2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember__us-gaap--ClassOfWarrantOrRightAxis__custom--AugustWarrantsMember_zZOaNLfZUZZb" title="Risk-free rate of interest (as a percent)">3.8% and expected warrant life of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250822__20250822__us-gaap--DebtInstrumentAxis__custom--August2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember__us-gaap--ClassOfWarrantOrRightAxis__custom--AugustWarrantsMember_zQQzFe10TUh1" title="Expected term (in years)">5.0 years. The fair value of the August Warrants was recorded as an additional debt discount to the notes payable. During the three months ended March 31, 2026, the Company recognized an aggregate of $<span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--August2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_z0qaNluE6Ue3" title="Amortization of debt discount">73,000 interest expense from the amortization of debt discount using the effective interest rate method. As of March 31, 2026, the outstanding balance under the August Future Financing Agreement was $<span id="xdx_908_eus-gaap--ShortTermBorrowings_iI_pn5n6_c20260331__us-gaap--DebtInstrumentAxis__custom--August2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zYOkTsKr2kv7" title="Short-term loan payable">1.2 million, net of debt discount of $<span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_pp0p0_c20260331__us-gaap--DebtInstrumentAxis__custom--August2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_z74RHVC0ukw9" title="Discount, current">104,000. September 2025 Future Receipts Financing Agreements On September 29, 2025, the Company entered into an agreement of sale of future receipts (“September Future Receipts Financing Agreement”) with Stage Advance, LLC (“Stage Advance”) by which Stage Advance purchased from the Company, its future accounts and contract rights arising from the sale of goods or rendition of services to the Company’s customers. The purchase price was $<span id="xdx_900_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20250929__20250929__us-gaap--DebtInstrumentAxis__custom--September2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zLlwcCjGt4I6" title="Proceeds from issuance of note payable">330,000, which was paid to the Company on September 29, 2025, net of a $<span id="xdx_901_eus-gaap--DebtInstrumentFeeAmount_iI_pp0p0_c20250929__us-gaap--DebtInstrumentAxis__custom--September2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_z2PUkDbeXNcb" title="Origination fee">6,600 origination fee. The Company also incurred a $<span id="xdx_90B_ecustom--DebtInstrumentBrokerageFees_c20250929__20250929__us-gaap--DebtInstrumentAxis__custom--September2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zOdafAmrXPwh" title="Brokerage fee">77,000 brokerage fee. The September Future Receipts Financing Agreement requires <span id="xdx_900_ecustom--DebtInstrumentNumberOfPeriodicPayments_dc_uInteger_c20250929__20250929__us-gaap--DebtInstrumentAxis__custom--September2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zETsXVIc2ljd" title="Number of periodic payments">twenty weekly payments of $<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20250929__20250929__us-gaap--DebtInstrumentAxis__custom--September2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zFPYII4Ky3Ze" title="Periodic payment">19,800 for a total repayment of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20250929__us-gaap--DebtInstrumentAxis__custom--September2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zARQ1PAptO0j" title="Aggregate principal amount">396,000 over the term of the agreement. During the three months ended March 31, 2026, the Company recognized an aggregate of $<span id="xdx_900_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--September2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zUE2OWnGNBV9" title="Amortization of debt discount">35,000 interest expense from the amortization of debt discount using the effective interest rate method. As of March 31, 2026, the outstanding balance under the September Future Financing Agreement was $<span id="xdx_901_eus-gaap--ShortTermBorrowings_iI_pp0p0_c20260331__us-gaap--DebtInstrumentAxis__custom--September2025FutureReceiptsFinancingAgreementsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zvyGuOaelUpi" title="Short-term loan payable">158,000. July 2025 Private Placement On July 22, 2025, the Company entered into <span id="xdx_90E_ecustom--DebtInstrumentNumberOfAgreementsEnteredInto_iI_dc_uInteger_c20250722__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zYqtuUfWndyh" title="Debt instrument, number of agreements entered into agreement">two security purchase agreements with two investors (the “Investors”) for the sale and issuance of two senior secured convertible notes (the “July 2025 Notes”) for an aggregate principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20250722__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zjy200ZENw78" title="Aggregate principal amount">3.8 million, with cash investment amount of $<span id="xdx_902_eus-gaap--ShortTermBorrowings_iI_pn5n6_c20250722__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z0DYfTpLYMS8" title="Short-term loan payable">3.0 million after <span id="xdx_904_ecustom--DebtInstrumentOriginalIssueDiscountPercent_iI_pid_dp_c20250722__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_ze7e86VJh2Fc" title="Debt instrument, original issue discount, percent">20% original issue discount of $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_pp0p0_c20250722__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zwc000DG3wBh" title="Discount, current">750,000. The Company received net cash proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromRepaymentsOfShortTermDebt_pn5n6_c20250722__20250722__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zrn31rrRWTy1" title="Net proceeds from short-term debt">2.8 million after repayment of certain obligations from the flow of funds. The July 2025 Notes mature on July 22, 2026, bear interest at <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20250722__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zQMbMpajVIlf" title="Interest rate">10% per annum on the original principal face amount and provide for other customary terms and covenants. The July 2025 Notes are not convertible for <span id="xdx_90B_ecustom--DebtInstrumentConvertibleNoteConversionWaitingPeriod_dtM_c20250722__20250722__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_ztTnU22MGEr6" title="Debt instrument, convertible, note conversion waiting period">4 months after execution and may be prepaid at any time without penalty. After the July 2025 Notes conversion waiting period of <span id="xdx_90B_ecustom--DebtInstrumentConvertibleNoteConversionWaitingPeriod_dtM_c20250722__20250722__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zSEKjher8wx8" title="Debt instrument, convertible, note conversion waiting period">4 months, the July 2025 Notes permit holders to convert outstanding principal and accrued interest into shares of common stock at a conversion price that is the lower of <span id="xdx_902_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_c20250722__20250722__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zzURu7Id1R32" title="Debt instrument, convertible, threshold trading days">80% of the trailing <span id="xdx_908_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_dc_uInteger_c20250722__20250722__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zSUJC83h5Wi7" title="Debt instrument, convertible, threshold trading days">ten-day volume weighted average price (“VWAP”) or a fixed maximum price, but with a floor price and certain caps on conversion pursuant to and limited by the terms of the notes, to prevent excessive dilution. The optional redemption includes an exercise contingency, which fails the equity classification guidance in ASC 815 and is thus precluded from being classified in equity. Therefore, the embedded derivatives are required to be bifurcated from the July 2025 Notes and accounted for at fair value at each reporting date. A fair value of $<span id="xdx_907_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_iI_pn5n6_c20250722__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zxkKBWW5U1Ba" title="Embedded derivative, fair value of embedded derivative liability">2.1 million was determined for the embedded derivative liabilities. The embedded derivative liabilities will be re-measured to fair value each reporting period until settlement (see Note 15). ProPhase Labs, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (unaudited) The Company also issued common stock purchase warrants to acquire up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250722__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JulyWarrantsMember_zuGylESlqmh6" title="Warrants (in shares)">525,000 shares of common stock (the “July Warrants”). The July Warrants are exercisable at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250722__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JulyWarrantsMember_zywdV4oyJPYj" title="Exercise price per share">5.00 per share (subject to adjustment) and expire <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250722__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JulyWarrantsMember_zOKc2nAJMw3d" title="Warrants outstanding, term">5 years from their date of issuance. The Company assessed the classification of the Warrants and determined that the Warrants are equity classified. The relative fair value of the July Warrants on the issuance date was $<span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20250722__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JulyWarrantsMember_zwWh9ArzUlTc" title="Warrant, fair value">1.3 million, which was recorded as an additional debt discount to the July 2025 Notes. The relative fair value was derived using the Black-Scholes option pricing model with the following assumptions: <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_do_c20250722__20250722__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JulyWarrantsMember_z2J7sGRAqdT2" title="Expected dividend yield (per share)">no dividend yield, expected volatility of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20250722__20250722__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JulyWarrantsMember_zu5KSVGTc2D4" title="Expected stock price volatility (as a percent)">97.9%, risk free interest rate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20250722__20250722__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JulyWarrantsMember_zXchl4YbjS7b" title="Risk-free rate of interest (as a percent)">3.9% and expected warrant life of <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250722__20250722__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JulyWarrantsMember_zwosQelix1Cb" title="Expected term (in years)">5.0 years. During the three months ended March 31, 2026, the Investors converted approximately $<span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zjr4M2yEnZx3" title="Debt Conversion, Converted Instrument, Amount">386,000 of the July 2025 Notes, including $<span id="xdx_90C_ecustom--DebtConversionConvertedInstrumentAccruedInterestAmount_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zlb1Sha5xCIk" title="Debt Conversion, Converted Instrument, Accrued Interest, Amount">7,000 accrued interest into <span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zdjJUOrOO6l5" title="Debt conversion, common stock">2,357,376 shares of the Company’s common stock. The aggregate fair value of the common stock issued on the conversion date was approximately $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zE5UvB47mn0d" title="Issuance of common stock to convert outstanding convertible notes and interest">511,000, which resulted a debt extinguishment loss of approximately $<span id="xdx_90A_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_znjSbo27rBq2" title="Debt extinguishment gain">126,000. The Company also extinguished approximately $<span id="xdx_90A_eus-gaap--ExtinguishmentOfDebtAmount_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zLdlz0zw4JDk" title="Extinguishment of debt, amount">126,000 embedded derivative liability upon the conversion, which was recognized as debt extinguishment gain on the condensed consolidated statement of operations. During the three months ended March 31, 2026, the Company recognized an aggregate of $<span id="xdx_90E_eus-gaap--AmortizationOfDebtDiscountPremium_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zi2BYlQLvG91" title="Amortization of debt discount">141,000 interest expense from the amortization of debt discount using the effective interest rate method. As of March 31, 2026, the remaining outstanding balance for the July 2025 Notes were approximately $<span id="xdx_90D_eus-gaap--ShortTermBorrowings_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zJh8o1h2e3Oi" title="Short-term loan payable">7,000 net of debt discount of $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--July2025NotesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zVNnglPQNeaa" title="Discount, current">15,000. ERC Claim and Risk Participation Agreement In August 2023, the Company filed for the Employee Retention Credit (“ERC”) for $<span id="xdx_90D_ecustom--EmployeeRetentionCreditReceivable_iI_pn5n6_c20230831__us-gaap--UnusualOrInfrequentItemAxis__custom--ERCClaimAndRiskParticipationAgreementMember_zhuYV5YUUGY3" title="Employee retention credit receivable">2.2 million. The ERC is a refundable tax credit for businesses that continued to pay employees while sustaining a full or partial suspension of operations limiting commerce, travel or group meetings due to COVID-19 pandemic and orders from an appropriate governmental authority or had significant declines in gross receipts from second quarter of 2020 to second quarter of 2021. The Company sustained a partial suspension of operations during this time due to governmental orders. Eligible employers can claim the ERC on an original or adjusted employment tax return for a period within those dates. On September 16, 2024 (“Agreement Date”), the Company, as seller, received $<span id="xdx_90C_ecustom--ProceedsFromSaleOfCompanyRightsTitleAndInterestToEmployeeRetentionCredit_pn5n6_c20240916__20240916__us-gaap--UnusualOrInfrequentItemAxis__custom--ERCClaimAndRiskParticipationAgreementMember__srt--CounterpartyNameAxis__custom--A1861AcquisitionLLCMember_zMCj1yNP8buk" title="Proceeds from sale of company rights, title and interest to employee retention credit">1.9 million as a purchase price (the “Purchase Price”) for the sale of the Company’s rights, title and interest per a Risk Participation of ERC Claim Agreement, dated September 13, 2024 (“Agreement”) by and between the Company and 1861 Acquisition LLC (the “Buyer”). The Company also incurred an issuance cost of $<span id="xdx_90E_ecustom--PaymentsOfIssuanceCostsForSaleOfCompanyRightsTitleAndInterestToEmployeeRetentionCredit_pp0p0_c20240916__20240916__us-gaap--UnusualOrInfrequentItemAxis__custom--ERCClaimAndRiskParticipationAgreementMember__srt--CounterpartyNameAxis__custom--A1861AcquisitionLLCMember_zfZTwBM6pQB4" title="Payments of issuance costs for sale of company rights, title and interest to employee retention credit">154,000. The Agreement transferred all of the Company’s rights to receive any and all payments, proceeds or distributions of any kind (without set-off, deduction or withholding of any kind), including interest, from the United States Internal Revenue Service (the “IRS”) in respect of the employee retention credits duly and timely claimed by Seller on account of qualified wages paid by Seller and identified as a “Claim for Refund” under Form 941-X Adjusted Employer’s Quarterly Federal Tax Return or Claim for Refund for the second (2nd), third (3rd) and fourth (4th) quarters of 2020, and the first (1st) and second (2nd) quarters of 2021 (the “Tax Refund Claim”) in the aggregate amount of $<span id="xdx_90F_ecustom--EmployeeRetentionCreditReceivableAmountTransferred_pn5n6_c20240916__20240916__us-gaap--UnusualOrInfrequentItemAxis__custom--ERCClaimAndRiskParticipationAgreementMember__srt--CounterpartyNameAxis__custom--A1861AcquisitionLLCMember_zLuwEHDz4wG3" title="Employee retention credit receivable, amount transferred">2.2 million (“Transferred Interests”). The Company expects the IRS to approve or deny its claim within the <span id="xdx_90E_ecustom--EmployeeRetentionCreditClaimApprovalPeriod_dtM_c20240916__20240916__us-gaap--UnusualOrInfrequentItemAxis__custom--ERCClaimAndRiskParticipationAgreementMember__srt--CounterpartyNameAxis__custom--A1861AcquisitionLLCMember_zk4r7Cf6IHg6" title="ERC claim approve or deny period (in months)">24 months from the Agreement Date. Upon approval and payment of the claim, the Company will settle the outstanding balance in cash to the Buyer. In the event that the IRS disallows all or a portion of the ERC, the Buyer has the demand right to put all or a part of the disallowed portion back to the Company at a price equal to <span id="xdx_90A_ecustom--EmployeeRetentionCreditPercentageOfImpairedAmountAllowedToBePutBackToTheCompany_iI_pid_dp_c20240916__us-gaap--UnusualOrInfrequentItemAxis__custom--ERCClaimAndRiskParticipationAgreementMember__srt--CounterpartyNameAxis__custom--A1861AcquisitionLLCMember_zcxqvJBlIwod" title="Percentage of impaired amount allowed to be put back to the company">85% of the impaired amount, plus interest at <span id="xdx_90A_ecustom--EmployeeRetentionCreditInterestRatePercentageOnImpairedAmountAllowedToBePutBackToTheCompany_iI_pid_dp_c20240916__us-gaap--UnusualOrInfrequentItemAxis__custom--ERCClaimAndRiskParticipationAgreementMember__srt--CounterpartyNameAxis__custom--A1861AcquisitionLLCMember_z9U8GiXusDMd" title="Interest rate percentage on impaired amount allowed to be put back to the company">10% per annum, calculated from the date of September 13, 2024 until payment is made. The Company elected to account for the ERC by analogy to IAS 20 when there was reasonable assurance of receipt, which was determined to be when the approval was received by the IRS. During the year ended December 31, 2025, the Company received approval for all refunds from the IRS in the amount of $<span id="xdx_905_eus-gaap--ProceedsFromIncomeTaxRefunds_pn5n6_c20250101__20251231__us-gaap--UnusualOrInfrequentItemAxis__custom--ERCClaimAndRiskParticipationAgreementMember__srt--CounterpartyNameAxis__custom--A1861AcquisitionLLCMember__us-gaap--DebtInstrumentAxis__custom--ERCClaimMember_zKSzOJIbQQsk" title="Proceeds from income tax refunds">2.2 million, of which $<span id="xdx_909_ecustom--ProceedsFromIncomeTaxRefundsPortionPassedThroughToBuyer_pn5n6_c20250101__20251231__us-gaap--UnusualOrInfrequentItemAxis__custom--ERCClaimAndRiskParticipationAgreementMember__srt--CounterpartyNameAxis__custom--A1861AcquisitionLLCMember__us-gaap--DebtInstrumentAxis__custom--ERCClaimMember_zn99UNyuFrV9" title="Proceeds from income tax refunds portion passed through to buyer">1.9 million was passed through to the Buyer and settled a portion of the ERC note and is included in other income on the condensed consolidated statements of operations, and the remaining of $<span id="xdx_90B_ecustom--DeferredTaxLiabilitiesAmountOffsetFromIncomeTaxRefunds_pp0p0_c20250101__20251231__us-gaap--UnusualOrInfrequentItemAxis__custom--ERCClaimAndRiskParticipationAgreementMember__srt--CounterpartyNameAxis__custom--A1861AcquisitionLLCMember__us-gaap--DebtInstrumentAxis__custom--ERCClaimMember_z3gOtfQKn6Qf" title="Outstanding tax liability">272,000 was offset the Company’s outstanding tax liability by the IRS. The offset against the IRS liabilities triggered the Seller’s put back right, and therefore the Company is required to repurchase back this portion at <span id="xdx_902_ecustom--EmployeeRetentionCreditPercentageOfImpairedAmountAllowedToBePutBackToTheCompany_iI_pid_dp_c20251231__us-gaap--UnusualOrInfrequentItemAxis__custom--ERCClaimAndRiskParticipationAgreementMember__srt--CounterpartyNameAxis__custom--A1861AcquisitionLLCMember__us-gaap--DebtInstrumentAxis__custom--ERCClaimMember_z5Tfoeii39kb" title="Repurchase percentage">85% at $<span id="xdx_905_eus-gaap--LongTermDebt_iI_pp0p0_c20251231__us-gaap--UnusualOrInfrequentItemAxis__custom--ERCClaimAndRiskParticipationAgreementMember__srt--CounterpartyNameAxis__custom--A1861AcquisitionLLCMember__us-gaap--DebtInstrumentAxis__custom--ERCClaimMember_zozCpF9bIMAb" title="Long term debt">231,000. As of March 31, 2026, the remaining outstanding balance under the Agreement was approximately $<span id="xdx_90D_eus-gaap--LongTermDebt_iI_pp0p0_c20260331__us-gaap--UnusualOrInfrequentItemAxis__custom--ERCClaimAndRiskParticipationAgreementMember__srt--CounterpartyNameAxis__custom--A1861AcquisitionLLCMember__us-gaap--DebtInstrumentAxis__custom--ERCClaimMember_zURifMzynZvc" title="Long term debt">231,000. Collateralized Loan Agreement On November 21, 2024 the Company entered into a financing agreement (the “2024 Collateralized Loan Agreement”) with CJEF Capital Partners PTE Ltd. (“CJEF”), to provide the Company with loan funding to be secured by <span id="xdx_90C_ecustom--DebtInstrumentCollateralAmountShares_iI_pid_c20241121__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourCollateralizedLoanAgreementMember_zJSWkmhnytP2" title="Number of common shares secured for loan">600,000 shares of common stock (the “2024 Collateralized Loan”). Funding is to be provided in tranches and shall mature 2 years from date of funding. Collateral retained by CJEF will be pledged and utilized to secure each funding and to be retained until all principal and interest have been paid. Interest will accrue on the outstanding principal amount of the 2024 Collateralized Loan at <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241121__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourCollateralizedLoanAgreementMember_zBFU6dqRnxhd" title="Interest rate">6% per annum (payable semi-annually in advance) and an arranger fee of <span id="xdx_909_ecustom--DebtInstrumentArrangerFeePercentage_pid_dp_c20241121__20241121__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourCollateralizedLoanAgreementMember_zSMPplM2Ke4f" title="Arranger fee">5% will be retained by CJEF from Loan proceeds. As of March 31, 2026, the Company has been provided funding of $500,000 against the 2024 Collateralized Loan agreement, with the entire balance remaining outstanding. On October 14, 2025, the Company entered into a Share Financing Agreement (the “2025 Collateralized Loan Agreement”) with Oceanview Consultant Partners Ltd. (“Oceanview”), to provide the Company with loan financing funding to be secured by Company’s common shares (the “2025 Collateralized Loan”). Funding is to be provided in tranches and shall mature 1 year from date of funding. the Company has been provided funding of $900,000 against the 2025 Collateralized Loan, with the entire balance remaining outstanding. As of March 31, 2026, approximately <span id="xdx_90F_ecustom--DebtInstrumentCollateralAmountShares_iI_pid_c20260331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFiveCollateralizedLoanAgreementMember_zZvIcF4HQNUc" title="Number of common shares secured for loan">1,360,000 common shares have been issued to secured the 2025 Collateralized Loan. Collateral retained by Oceanview will be pledged and utilized to secure each funding and is to be retained until all principal and interest have been paid. Interest will accrue on the outstanding principal amount of the Collateralized Loan at <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20260331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFiveCollateralizedLoanAgreementMember_zh5CqaiLlEe3" title="Interest rate">6% per annum, with interest only payable monthly and an arranger fee of <span id="xdx_90D_ecustom--DebtInstrumentArrangerFeePercentage_pid_dp_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFiveCollateralizedLoanAgreementMember_zqqrXs1SF8r3" title="Arranger fee">6% will be retained by Oceanview from Loan proceeds. ProPhase Labs, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (unaudited)

0.10

240000

0.75

190000

40000

10000

264000

80000

0.10

180000

140000

30000

10000

75000

0.0499 180

0.80

0.10

78000

55000

13000

10000

0.0499 180

0.80

308000

80000

3450

36000 18

6444

116000

70000

33000

220000

8800

69000 25

11000

289000

209000

68000

2 2

P12M

625000

125000

0.10

500000

50000

6.00

P5Y

115000

0.984

0.040

P5Y

500000

433000

50000

115000

100000

15000

126750

3000

129000

126000

62000

813362

113000

51000

150000

9452

159452

400000

76000

P10Y

528000

4 P6M

18000

238000

289000

287000

85000

1010875

144000

59000

135000

28000

P10Y

181000

4 P6M

12000

50000

8000

P10Y

64000

4 P6M

3000

75000

19000

P10Y

105000

4 P6M

7000

700000

188000

553000

120083

1400000

50000

5.00

P5Y

120000

0.983

0.038

P5Y

73000

1200000

104000

330000

6600

77000 20

19800

396000

35000

158000

3800000

3000000.0

0.20

750000

2800000

0.10

P4M P4M

0.80

2100000

525000

5.00

P5Y

1300000

0.979

0.039

P5Y

386000

7000

2357376

511000

126000

141000

7000

15000

2200000 1900000 154000 2200000 P24M 0.85 0.10

2200000

1900000 272000 0.85

231000

600000

P2Y

0.06

0.05

500000

P1Y

900000

1360000

0.06

Note 6 - Stockholders’ Equity Preferred Stock The preferred stock authorized under our certificate of incorporation may be issued from time to time in one or more series. As of March 31, 2026 and December 31, 2025, no shares of preferred stock had been issued. Common Stock Dividends No dividends were declared during the three ended March 31, 2026 and 2025. Common Stock Common ATM Offering On December 19, 2025, the Company entered into an Sales Agreement (the “2025 Sales Agreement”) with WestPark Capital, Inc. (the “WestPark”), pursuant to which the Company may offer and sell, from time to time through WestPark, shares of our common stock having an aggregate offering price of up to $<span id="xdx_90C_ecustom--SaleOfStockAggregateInitialOfferingPriceMaximum_pn5n6_c20251219__20251219__srt--CounterpartyNameAxis__custom--WestParkCapitalIncMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingMember_zjD8A7d7rFBk" title="Aggregate offering price">5.3 million, subject to the terms and conditions of the Sales Agreement. WestPark is entitled to a commission equal to <span id="xdx_90C_ecustom--SaleOfStockCommissionPercentage_pid_dp_c20251219__20251219__srt--CounterpartyNameAxis__custom--WestParkCapitalIncMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingMember_zBHZJWCEPwJc" title="Sale of stock, commission percentage">3% of the gross sales price per share for all shares sold through it as our agent, and the Company will receive the net proceeds after deducting this commission and any offering expenses. During the three months ended March 31, 2026, the Company issued <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pid_c20260101__20260331__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingMember_zNSPXX1qo2h8" title="Shares authorized">163,900 shares of common stock pursuant to the 2025 Sales Agreement. The Company received cash proceeds of $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pid_c20260101__20260331__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingMember_zF0XHr6tw47k" title="Sale of stock, consideration received on transaction">40,000, which was net of issuance cost of $30,000. 2026 Equity Line of Credit – Generating Alpha On January 16, 2026, the Company entered into a Stock Purchase Agreement (“the Agreement”) with Generating Alpha Ltd. (“the Investor”), pursuant to which the Investor committed to provide the Company with up to ten million dollars ($10,000,000) of equity capital over time, at the Company’s election and subject to the terms and conditions set forth in the Agreement. The Agreement establishes an equity line facility that provides the Company with the right, but not the obligation, to sell shares of common stock to the Investor from time to time. The Company retains full discretion over its access to the facility and there is no requirement that the Company access the facility at any time. In connection with entering into the Agreement, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260116__20260116__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zt1mDmBRFZjb" title="Stock issued during the period, shares">549,105 shares of common stock and a prefunded common stock purchase warrant to acquire up to <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260116__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVR9PbbIOEp7" title="Warrants rights to acquire">240,369 shares of common stock as a commitment fee. The warrant has an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260116__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPfr2lT14oUc" title="Warrants Exercise price">0.00 per share and is exercisable on a cashless basis, subject to customary ownership limitations. During the three months ended March 31, 2026, the Company did <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260101__20260331__srt--CounterpartyNameAxis__custom--ThinkEquityLLCMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingMember_zbSb9rgD9sJc" title="Aggregate offering price">not issue any shares of common stock pursuant to the Agreement. The 2025 Directors’ Equity Compensation Plan On September 9, 2025, the stockholders of the Company approved the 2025 Directors’ Equity Compensation Plan (the “2025 Directors’ Plan”) at the 2025 Special Meeting. The 2025 Directors’ Plan amended and restated the Company’s Amended and Restated 2022 Directors’ Equity Compensation Plan and provided for an increase in the number of shares reserved for issuance under the plan by <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pid_c20250909__20250909__us-gaap--PlanNameAxis__custom--TwoThousandsTwentyFiveDirectorsPlanMember_zlQBPEutdHai" title="Increase in the number of shares reserved for issuance">50,000 shares. During the three months ended March 31, 2026, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_do_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwoThousandsTwentyFiveDirectorsPlanMember_zHnQget7jigk" title="Shares issued">no stock options were issued under the 2025 Directors’ Plan. As of March 31, 2026, the number of shares authorized for issuance under the 2025 Directors Plan was <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandsTwentyFiveDirectorsPlanMember_zGCqGM11Ye6l" title="Shares authorized">60,000, which included the number of shares available under the 2022 Directors Plan immediately prior the stockholder approval of the 2025 Directors’ Plan as described below. The 2022 Directors’ Equity Compensation Plan On May 19, 2022, the stockholders of the Company approved the 2022 Directors’ Equity Compensation Plan (the “2022 Directors’ Plan”) at the 2022 Annual Meeting of Stockholders of the Company (the “2022 Annual Meeting”). The 2022 Directors’ Plan amended and restated the Company’s Amended and Restated 2010 Directors’ Equity Compensation Plan and provided for an increase in the number of shares reserved for issuance under the plan by <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pid_c20220519__20220519__us-gaap--PlanNameAxis__custom--TwoThousandsTwentyFiveDirectorsPlanMember_zxk6ZpPiXhHj" title="Shares authorized">30,000 shares and for the adjustment of the per share exercise price of stock options granted under the 2022 Plan in the event of any change in the outstanding shares of common stock of the Company as a result of, among other things, any distribution or special dividend to stockholders of shares, cash or other property (other than regular cash dividends). ProPhase Labs, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (unaudited) On June 16, 2023 the stockholders of the Company approved the Amended and Restated 2022 Directors’ Equity Compensation Plan (the “Amended 2022 Directors’ Plan”) at the 2023 Annual Meeting of Stockholders of the Company. The Amended 2022 Directors’ Plan provides for an increase in the number of shares reserved for issuance under such plan by <span id="xdx_904_ecustom--CommonStockIncreaseDecreaseInCapitalSharesReservedForFutureIssuance_iI_pid_c20230616__us-gaap--PlanNameAxis__custom--AmendedTwoThousandsTwentyTwoDirectorsPlanMember_z9bFzHWnCLm1" title="Increase in shares for issuance">15,000 shares. During the three months ended March 31, 2026, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_do_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwoThousandsTwentyFiveDirectorsPlanMember_ziUHmAwJzfv2" title="Shares issued">no stock options were issued under the 2025 Directors’ Plan. There were 10,000 shares of common stock available to be issued under the 2022 Directors’ Plan immediately prior the stockholder approval of the 2025 Directors’ Plan. The 2025 Equity Compensation Plan On September 9, 2025, the stockholders of the Company approved the 2025 Equity Compensation Plan (the “2025 Plan”) at the 2025 Special Meeting. The 2025 Plan amended and restated the Company’s Amended and Restated 2022 Equity Compensation Plan and provided for an increase in the number of shares reserved for issuance under the plan by <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pid_c20250909__20250909__us-gaap--PlanNameAxis__custom--TwoThousandsTwentyFivePlanMember_zhraA04HR6d4" title="Increase in the number of shares reserved for issuance">300,000 shares. During the three months ended March 31, 2026, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_do_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwoThousandsTwentyFiveDirectorsPlanMember_zqtz6I4glo81" title="Shares issued">no stock options issued under the 2025 Plan. As of March 31, 2026, the number of shares authorized for issuance under the 2025 Plan was <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandsTwentyFivePlanMember_zR1WR0cKKYO2" title="Shares authorized">233,203, which included the number of shares available under the 2022 Plan immediately prior the stockholder approval of the 2025 Plan as described below. The 2022 Equity Compensation Plan On May 9, 2022, the stockholders of the Company approved the 2022 Equity Compensation Plan (the “2022 Plan”) at the 2022 Annual Meeting. The 2022 Plan amended and restated the Company’s Amended and Restated 2010 Equity Compensation Plan and provided for an increase in the number of shares reserved for issuance under the plan by 1,00,000 shares and for the adjustment of the per share exercise price of stock options granted under the 2022 Plan in the event of any change in the outstanding shares of common stock of the Company as a result of, among other things, any distribution or special dividend to stockholders of shares, cash or other property (other than regular cash dividends). During the three months ended March 31, 2026, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_do_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwoThousandsTwentyFiveDirectorsPlanMember_zPL1AEyN8NLc" title="Shares issued">no stock options issued under the 2025 Plan. There were 3,375 shares of common stock available to be issued under the 2022 Plan immediately prior the stockholder approval of the 2025 Plan. Summary of all option grants The following table summarizes stock option activity during the three months ended March 31, 2026, (in thousands, except per share data). Schedule of Stock Options Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life (in years)</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Outstanding as of January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20260101__20260331_zo6UilBGFcV6" style="width: 10%; text-align: right" title="Number of shares, outstanding, beginning">478</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260331_zSTqnNmEefi6" style="width: 10%; text-align: right" title="Weighted average exercise price, outstanding, beginning">48.60</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zEIzLz8MgFl3" title="Weighted average remaining contractual life, outstanding shares (in years)">4.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20260101__20260331_z3YNle6PeAXe" style="width: 10%; text-align: right" title="Total intrinsic value, outstanding, beginning">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20260101__20260331_zv29UFRHW4Q4" style="text-align: right" title="Number of shares options granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331_zuvluRazDTqj" style="text-align: right" title="Weighted average exercise price, granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Forfeited/exprired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20260101__20260331_zjtYGDSilQx7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares options forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331_zYLsvUew7oVa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; padding-bottom: 2.5pt">Outstanding as of March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20260101__20260331_z67Ph5MRZ3nd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding, ending">478</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260331_zzB4cDnX96u" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding, ending">48.60</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331_zUXuKgEjgZv9" title="Weighted average remaining contractual life, outstanding shares (in years)">4.3</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20260101__20260331_zgnGIfOvT4Y1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total intrinsic value, outstanding, ending">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Options vested and exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20260101__20260331_zJ1NoBe68VL5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options vested and exercisable">340</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20260101__20260331_z7nVIEdsaNub" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, options vested and exercisable">53.72</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331_zyXDrfZrFPmi" title="Weighted average remaining contractual life, options vested and exercisable (in years)">3.9</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_pn3n3_c20260101__20260331_zxLM88oflvd1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total intrinsic value, options vested and exercisable">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the closing stock price of $0.09 for the Company’s common stock on March 31, 2026. ProPhase Labs, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (unaudited) Stock Warrants The following table summarizes warrant activity during the three months ended March 31, 2026 (in thousands, except per share data): Schedule of Warrant Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life (in years)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding as of January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pn3n3_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNjw5i65PICl" style="width: 12%; text-align: right" title="Number of shares, warrants outstanding, beginning">757</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1_iS_pid_uUSDPShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4zHuSAnbLw4" style="width: 12%; text-align: right" title="Weighted average exercise price, warrants outstanding, beginning">9.58</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEOHIaICe0va" title="Weighted average remaining contractual life, outstanding shares">4.4</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Granted</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pn3n3_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zv56gwssLNa4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, warrants granted">240</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingGrantedWeightedAverageExercisePrice1_pid_uUSDPShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIpWmXSfLH9i" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants granted">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5.3</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding as of March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pn3n3_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zu4XfJwvFxqd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants outstanding, ending">997</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1_iE_pid_uUSDPShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAd2xnzsxWVb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, warrants outstanding, ending">7.27</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSi1c1YTTie" title="Weighted average remaining contractual life, outstanding shares">4.4</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Warrants vested and exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrebPs4rGtSk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants vested and exercisable">997</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExercisableWeightedAverageExercisePrice1_iE_pid_uUSDPShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zI0KXBxQ0k7d" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, warrants vested and exercisable">7.27</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--WeightedAverageRemainingContractualLifeWarrantsVestedAndExercisable_dtY_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUqlQQshWui3" title="Weighted average remaining contractual life, warrants vested and exercisable">4.4</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> During the three months ended March 31, 2026, the Company granted warrants to purchase 240,369 shares of the Company’s common stock in connection with entering into the 2026 Equity Line of Credit agreement as a commitment fee. The warrant has an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260116__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8JDqzUtL8Sl" title="Warrants Exercise price">0.00 per share and is exercisable on a cashless basis, subject to customary ownership limitations. The fair value of the warrants was $0.16 per share which was equal to the stock price on the issuance date. The Company recognized approximately $438,000 and $372,000 of share-based compensation expense during the three months ended March 31, 2026 and 2025, respectively. The Company will recognize an aggregate of approximately $2.1 million of remaining share-based compensation expense related to outstanding stock options over a weighted average period of 2.5 years.

5300000 0.03

163900

40000

30000

10000000

549105

240369

0.00

50000

60000

30000

15000

10000

300000

233203

100000

3375

The following table summarizes stock option activity during the three months ended March 31, 2026, (in thousands, except per share data). Schedule of Stock Options Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life (in years)</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Outstanding as of January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20260101__20260331_zo6UilBGFcV6" style="width: 10%; text-align: right" title="Number of shares, outstanding, beginning">478</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260331_zSTqnNmEefi6" style="width: 10%; text-align: right" title="Weighted average exercise price, outstanding, beginning">48.60</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zEIzLz8MgFl3" title="Weighted average remaining contractual life, outstanding shares (in years)">4.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20260101__20260331_z3YNle6PeAXe" style="width: 10%; text-align: right" title="Total intrinsic value, outstanding, beginning">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20260101__20260331_zv29UFRHW4Q4" style="text-align: right" title="Number of shares options granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331_zuvluRazDTqj" style="text-align: right" title="Weighted average exercise price, granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Forfeited/exprired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20260101__20260331_zjtYGDSilQx7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares options forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331_zYLsvUew7oVa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; padding-bottom: 2.5pt">Outstanding as of March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20260101__20260331_z67Ph5MRZ3nd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding, ending">478</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260331_zzB4cDnX96u" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding, ending">48.60</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331_zUXuKgEjgZv9" title="Weighted average remaining contractual life, outstanding shares (in years)">4.3</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20260101__20260331_zgnGIfOvT4Y1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total intrinsic value, outstanding, ending">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Options vested and exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20260101__20260331_zJ1NoBe68VL5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options vested and exercisable">340</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20260101__20260331_z7nVIEdsaNub" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, options vested and exercisable">53.72</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331_zyXDrfZrFPmi" title="Weighted average remaining contractual life, options vested and exercisable (in years)">3.9</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_pn3n3_c20260101__20260331_zxLM88oflvd1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total intrinsic value, options vested and exercisable">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

478000

48.60

P4Y7M6D

478000

48.60

P4Y3M18D

340000

53.72

P3Y10M24D

0.09

The following table summarizes warrant activity during the three months ended March 31, 2026 (in thousands, except per share data): Schedule of Warrant Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life (in years)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding as of January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pn3n3_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNjw5i65PICl" style="width: 12%; text-align: right" title="Number of shares, warrants outstanding, beginning">757</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1_iS_pid_uUSDPShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4zHuSAnbLw4" style="width: 12%; text-align: right" title="Weighted average exercise price, warrants outstanding, beginning">9.58</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEOHIaICe0va" title="Weighted average remaining contractual life, outstanding shares">4.4</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Granted</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pn3n3_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zv56gwssLNa4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, warrants granted">240</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingGrantedWeightedAverageExercisePrice1_pid_uUSDPShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIpWmXSfLH9i" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants granted">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5.3</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding as of March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pn3n3_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zu4XfJwvFxqd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants outstanding, ending">997</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1_iE_pid_uUSDPShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAd2xnzsxWVb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, warrants outstanding, ending">7.27</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSi1c1YTTie" title="Weighted average remaining contractual life, outstanding shares">4.4</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Warrants vested and exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrebPs4rGtSk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants vested and exercisable">997</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExercisableWeightedAverageExercisePrice1_iE_pid_uUSDPShares_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zI0KXBxQ0k7d" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, warrants vested and exercisable">7.27</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--WeightedAverageRemainingContractualLifeWarrantsVestedAndExercisable_dtY_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUqlQQshWui3" title="Weighted average remaining contractual life, warrants vested and exercisable">4.4</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

757000

9.58

P4Y4M24D

240000

997000

7.27

P4Y4M24D

997000 7.27 P4Y4M24D

240369

0.00

0.16

438000

372000

2100000

P2Y6M

Note 7 – Income Taxes We recognize tax assets and liabilities for future tax consequences related to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and for net operating loss carryforwards. Management evaluated the deferred tax assets for recoverability using a consistent approach that considers the relative impact of negative and positive evidence, including historical profitability and projections of future reversals of temporary differences and future taxable income. We are required to establish a valuation allowance for deferred tax assets if management determines, based on available evidence at the time the determination is made, that it is not more likely than not that some portion or all of the deferred tax assets will be realized. As a result of historical losses from continuing operations, we have recorded a full valuation allowance against the net deferred tax assets. Judgment is required to estimate forecasted future taxable income, which may be impacted by future business developments, actual results, tax initiatives, legislative, and other economic factors. The Company will continue to monitor income levels and potential changes to its operating and tax model, and other legislative or global developments in its determination. ProPhase Labs, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (unaudited)

Note 8 – Commitments and Contingencies License Agreements Linebacker LB1 and LB2 In July 19, 2022, the Company through its wholly-owned subsidiary ProPhase BioPharma entered into a License Agreement (the “Linebacker License Agreement”) with Global BioLife, Inc. (the “Licensor”), with an effective date of July 18, 2022 (the “Linebacker Effective Date”), pursuant to which it acquired from Licensor a worldwide exclusive right and license under certain patents identified in the Linebacker License Agreement (the “Licensed Patents”) and know-how (collectively, the “Licensed IP”) to exploit any compound covered by the Licensed Patents (the “Licensed Compound”), including Linebacker LB1 and LB2, and any product comprising or containing a Licensed Compound (“Licensed Products”) in the treatment of cancer, inflammatory diseases or symptoms, memory-related syndromes, diseases or symptoms including dementia and Alzheimer’s Disease (the “Field”). Under the terms of the Linebacker License Agreement, the Licensor reserves the right, solely for itself and for GRDG Sciences, LLC (“GRDG”) to use the Licensed Compound and Licensed IP solely for research purposes inside the Field and for any purpose outside the Field. Subject to certain conditions set forth in the Linebacker License Agreement, the Company may grant sublicenses (including the right to grant further sublicenses) to its rights under the Linebacker License Agreement to any of its affiliates or any third party with the prior written consent of Licensor, which consent may not be unreasonably withheld. Either party to the Linebacker License Agreement may assign its rights under the Linebacker License Agreement (i) in connection with the sale or transfer of all or substantially all of its assets to a third party, (b) in the event of a merger or consolidation with a third party or (iii) to an affiliate; in each case contingent upon the assignee assuming in writing all of the obligations of its assignor under the Linebacker License Agreement. Under the terms of Linebacker License Agreement, the Company is required to pay to Licensor a one-time upfront license fee of $50,000 within ten days of the Linebacker Effective Date and must pay an additional $900,000 following the achievement of a first Phase 3 study which may be required by FDA for the first Licensed Product and an additional $<span id="xdx_907_ecustom--AdditionalPaymentOfFee_pn6n6_c20220719__20220719__us-gaap--TypeOfArrangementAxis__custom--LinebackerLicenseAgreementsMember__us-gaap--AwardTypeAxis__custom--NewDrugApplicationMember_zIG7kQ0t1qfk" title="Additional payment of fee">1.0 million upon the receipt of regulatory approval of a New Drug Application for the first Licensed Product. During the term of the Linebacker License Agreement, the Company is also required to pay to Licensor <span id="xdx_907_ecustom--LicenseOrRoyaltyNetRevenuePercentage_pid_dp_uPure_c20220719__20220719__us-gaap--TypeOfArrangementAxis__custom--LinebackerLicenseAgreementsMember_zjFZH4zokArh" title="License or royalty net revenue percentage">3% royalties on Net Revenue (as defined in the Linebacker License Agreement) of each Licensed Product, but no less than a minimum royalty of $250,000 of Net Revenue per year minus any royalty payments for any required third party licenses. In connection with the Linebacker License Agreement, the Company did not incur any expenses for the three months ended March 31, 2026 and 2025, respectively. No clinical studies have begun under this agreement. Equivir In March 2023, we commenced patient enrollment in a randomized, placebo-controlled clinical trial of Equivir to evaluate its effect on upper respiratory tract infections. Vedic Lifesciences, a leading clinical research organization, is contracted to conduct the combination prophylactic and therapeutic study, which will be conducted at 8 sites. We currently anticipate trial completion launching Equivir (dietary supplement) in the United States toward the end of 2025. In connection with the license agreement relating to Equivir, for the three months ended March 31, 2026 and 2025, the Company did not incur any expenses for the three months ended March 31, 2026 and 2025, respectively. ProPhase Labs, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (unaudited) BE-Smart™ Esophageal Pre-Cancer Diagnostics Screening Test In March 2023, in connection with the asset acquisition of Stella Diagnostics, Inc., we announced a collaboration for the continued development of our BE-Smart™ Esophageal Pre-Cancer diagnostic screening test. The BE-Smart™ test is designed to detect molecular biomarkers associated with Barrett’s Esophagus and progression to esophageal adenocarcinoma. On June 17, 2025, we announced the successful completion of a key validation study for the BE-Smart™ molecular diagnostic test. The study demonstrated a technical success rate greater than 95% using esophageal brush cytology samples, confirming the test’s compatibility and reliability with both traditional forceps biopsy and less invasive brush biopsy techniques. Based on these results, we are continuing commercialization of BE-Smart™ as a Laboratory Developed Test (“LDT”) and Research Use Only (“RUO”) product, with steps towards commercialization planned for the third quarter of 2025 and broader insurance-backed commercialization targeted for 2026. These timelines are forward-looking statements and are subject to various risks and uncertainties, including, but not limited to, regulatory developments, payer coverage decisions, and market adoption rates. On March 31, 2025, the U.S. District Court for the Eastern District of Texas vacated the U.S. Food and Drug Administration’s (“FDA”) Final Rule that would have expanded FDA oversight of LDTs, holding that the agency exceeded its statutory authority. The court remanded the matter to the Department of Health and Human Services for reconsideration. The FDA did not appeal within the 60-day period, which ended May 30, 2025, and, as a result, the rule is no longer in effect and compliance deadlines are not enforceable. Oversight of LDTs, including BE-Smart™, currently reverts to the existing Clinical Laboratory Improvement Amendments (“CLIA”) framework administered by the Centers for Medicare & Medicaid Services. Future legislative or regulatory action could alter this framework. As a result certain LDTs, including BE-Smart™, are not currently subject to direct FDA oversight, allowing for a faster market entry while maintaining rigorous internal validation and quality control standards. If new requirements were imposed, we could be required to obtain pre-market clearance or approval before commercialization, which could delay our market entry, increase development and regulatory costs, and potentially require changes to the test. Based on published industry data and internal estimates, the U.S. market for the test is approximately <span id="xdx_902_ecustom--CollaborativeArrangementEstimatedAnnualProcedures_pn6n6_c20250331__20250331__us-gaap--TypeOfArrangementAxis__custom--BESmartLicenseAgreementsMember__srt--RangeAxis__srt--MinimumMember_znGmF3kwXWd4" title="Collaborative arrangement, estimated annual procedures">6 to <span id="xdx_907_ecustom--CollaborativeArrangementEstimatedAnnualProcedures_pn6n6_c20250331__20250331__us-gaap--TypeOfArrangementAxis__custom--BESmartLicenseAgreementsMember__srt--RangeAxis__srt--MaximumMember_zfolL0yOOIQ7" title="Collaborative arrangement, estimated annual procedures">7 million endoscopic procedures annually, representing an addressable market opportunity of over $<span id="xdx_902_ecustom--CollaborativeArrangementEstimatedMarketOpportunityValue_pn9n9_c20250331__20250331__us-gaap--TypeOfArrangementAxis__custom--BESmartLicenseAgreementsMember_zF3Febj74uO3" title="Collaborative arrangement, estimated market opportunity value">10 billion. The market opportunity estimate reflects management’s judgment, is based on available industry data, and is subject to inherent uncertainties. For the three months ended March 31, 2026 and 2025, we did not incur any expenses related to the BE-Smart™ license agreement. On August 6, 2025, the United States Patent and Trademark Office issued U.S. Patent No. 12,379,378 B2, covering the BE-Smart™ Esophageal Pre-Cancer Diagnostic Screening Test. This newly issued patent further strengthens our intellectual property position for BE-Smart™ technology and supports our continued efforts to commercialize the test for early detection and risk stratification of Barrett’s esophagus and related esophageal conditions. We continue to own the full intellectual property portfolio supporting the BE-Smart™ test, including a foundational patent family covering molecular markers of esophageal disease progression, with issued patents and pending applications expected to provide protection until 2040. We remain positioned to capitalize on favorable regulatory and clinical practice trends supporting minimally invasive screening methods, although there can be no assurance that commercialization will occur within the anticipated timeframe or that adoption will meet our expectations. ProPhase Labs, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (unaudited) Litigation The Company is involved in various legal proceedings arising in the ordinary course of business, including matters relating to commercial contracts, lease obligations, accounts receivable collections, and bankruptcy-related proceedings associated with ProPhase Diagnostics, Inc. and its subsidiaries. Certain of these matters are described in Part II, Item 1, “Legal Proceedings,” of this Quarterly Report, which disclosure is incorporated herein by reference. Management evaluates litigation contingencies on a quarterly basis in accordance with ASC 450, Contingencies. As of March 31, 2026, amounts have been accrued for matters where a loss is considered probable and reasonably estimable. For other matters, management either believes an unfavorable outcome is not probable or cannot reasonably estimate the possible loss or range of loss. Accordingly, no additional accruals have been recorded. The ultimate resolution of these matters could differ from current estimates and may have a material effect on future operating results, cash flows, or financial position.

50000000 P10D 900000000 1000000.0 0.03

250000000

6000000 7000000 10000000000

Note 9 – Leases Operating Leases New Jersey Laboratory Lease On October 23, 2020, we completed the acquisition of CPM, which included a <span id="xdx_900_eus-gaap--AreaOfRealEstateProperty_iI_usqft_c20201023__us-gaap--BusinessAcquisitionAxis__custom--CPMMember__us-gaap--GeographicDistributionAxis__custom--OldBridgeNewJerseyMember_zXHY0Uthjnv9" title="Area of real estate property">4,000 square foot CLIA accredited laboratory located in Old Bridge, New Jersey, which was owned by CPM (which is now known as ProPhase Diagnostics NJ, Inc.). The lease was renewed in February 2023, for an additional <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtM_c20201023__us-gaap--BusinessAcquisitionAxis__custom--CPMMember__us-gaap--GeographicDistributionAxis__custom--OldBridgeNewJerseyMember_zOyT81oI87W2" title=" Operating lease, renewal term">36 months until February 2026. The monthly base is $<span id="xdx_90C_ecustom--LesseeOperatingLeaseMonthlyBaseRent_c20201023__20201023__us-gaap--BusinessAcquisitionAxis__custom--CPMMember__us-gaap--GeographicDistributionAxis__custom--OldBridgeNewJerseyMember_zCI7QSwN47md" title="Operating lease, monthly base rent">5,500 per month. The lease renewal resulted in the recognition of an additional right-of-use asset and operating lease liability of $<span id="xdx_901_eus-gaap--OperatingLeaseLiability_iI_c20201023__us-gaap--BusinessAcquisitionAxis__custom--CPMMember__us-gaap--GeographicDistributionAxis__custom--OldBridgeNewJerseyMember_zwTFQYjWrFB2" title="Operating lease, liability">170,000, respectively in Fiscal 2023. As a result of the deconsolidation of PDX (see Note 14), the operating lease liability and right-of-use asset associated with the New Jersey operating lease was derecognized on the Company’s condensed consolidated balance sheet as of March 31, 2026. New York Second Floor Lease On December 8, 2020, the Company entered into a Lease Agreement (the “NY Second Floor Lease”) with BRG Office L.L.C. and Unit 2 Associates L.L.C. (the “Landlord”), pursuant to which the Company leases certain premises located on the second floor (the “Second Floor Leased Premises”) of 711 Stewart Avenue, Garden City, New York (the “Building”). The Second Floor Leased Premises serve as the Company’s second location and corporate headquarters, offering a wide range of laboratory testing services for diagnosis, screening and evaluation of diseases, including COVID-19 and Respiratory Pathogen Panel Molecular tests. On June 10, 2022, the Company entered into a First Amendment to the NY Second Floor Lease (the “Second Floor Lease Amendment”). The Second Floor Lease Amendment amends the NY Second Floor Lease to provide that any uncured default by the Company or any of its affiliate under the NY First Floor Lease (defined below) will constitute a default by the Company under the NY Second Floor Lease. On March 1, 2025, the Company entered into a Surrender Agreement with the Landlord, pursuant to which the Company agreed to surrender the Second Floor Leased Premises on or before May 30, 2025 (the “Surrender Date”). Under the agreement, the Company will remain responsible for rent and other charges through the Surrender Date and will pay the Landlord a settlement amount of approximately $<span id="xdx_90B_ecustom--OperatingLeaseSurrenderSettlementAmountMonthly_c20250301__20250301__us-gaap--GeographicDistributionAxis__custom--NewYorkSecondFloorLeaseMember_z3AogHOwRgQk" title="Operating lease, settlement amount">740,000 in <span id="xdx_903_ecustom--OperatingLeaseNumberOfSurrenderSettlementInstallments_dc_c20250301__20250301__us-gaap--GeographicDistributionAxis__custom--NewYorkSecondFloorLeaseMember_zEhtFTmECAIb" title="Operating lease, settlement installments">seven equal monthly installments from June 1, 2025 through December 1, 2025. Upon timely performance of the Company’s obligations under the Surrender Agreement, the NY Second Floor Lease will be deemed terminated as of the Surrender Date, and the Company will have no further obligations thereunder, other than as set forth in the Surrender Agreement. As of the date of this report, the Company has made all required payments under the Surrender Agreement. As of the date of this report, the Company has made all required payments under the Surrender Agreement. New York First Floor Lease On June 10, 2022, the Company entered into a second Lease Agreement (the “NY First Floor Lease”) with Landlord, pursuant to which the Company leases approximately 4,516 sq. feet located on the first floor (the “NY First Floor Leased Premises”) of the Building. As described above, the Company currently leases space on the second floor of the Building. The First Floor Lease was terminated in 2025. Finance Leases On April 19, 2023, the Company entered into a master lease agreement for laboratory equipment (the “First Equipment Lease”) with a vendor. The First Equipment Lease has a 5-year term and is recognized as a finance lease under ASC 842. The present value of the minimum future obligations of $1.5 million at inception was calculated based on an interest rate of 8.0%, which was recognized in finance lease liabilities in the condensed consolidated balance sheet. On July 21, 2023, the Company entered into a master lease agreement for a laboratory equipment (the “Second Equipment Lease”) with a vendor. The Second Equipment Lease has a 4-year term and is recognized as a finance lease under ASC 842. The present value of the minimum future obligations of $5.1 million at inception was calculated based on an interest rate of 7.4%, which was recognized in finance lease liabilities in the condensed consolidated balance sheet. At March 31, 2026 and December 31, 2025, the Company had finance lease liabilities of approximately $3.5 million and $2.8 million, respectively, and finance lease assets within property and equipment, net of approximately $1.7 million and $2.0 million, respectively, which were included in the condensed consolidated balance sheets. ProPhase Labs, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (unaudited) The following summarizes quantitative information about our operating leases (amounts in thousands): Schedule of Quantitative Information about Operating and Finance Leases <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20260101__20260331_z1CPC75r4oQe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_497_20250101__20250331_zOuKodVB5IOc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Operating leases:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr id="xdx_403_eus-gaap--OperatingLeaseCost_pn3n3_maOLEzgix_zfwKlVV7pkp1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Operating lease expense</td><td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">239</td><td style="width: 1%; text-align: left"> </td> </tr> <tr id="xdx_405_eus-gaap--OperatingLeaseExpense_iT_pn3n3_mtOLEzgix_zK7I2igWkYK8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Total operating lease expense</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">239</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Finance leases:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr id="xdx_403_eus-gaap--FinanceLeaseInterestExpense_pn3n3_maFLCztAr_zygLpX3svDyh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Interest lease cost</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">38</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">83</td><td style="text-align: left"> </td> </tr> <tr id="xdx_407_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_pn3n3_maFLCztAr_zbOxuUDgJJ15" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Depreciation expense</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">317</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">392</td><td style="text-align: left"> </td> </tr> <tr id="xdx_406_ecustom--FinanceLeaseCost_iT_pn3n3_mtFLCztAr_zVn3If8yR2G6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Total finance lease expense</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">355</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">475</td><td style="text-align: left"> </td> </tr> </table> Other information related to the Company’s leases is shown below (dollar amounts in thousands): <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_492_20260101__20260331_zrB8fDH0tWH7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20250101__20250331_z7ciSUFFhmk5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingLeasePayments_iN_pn3n3_di_zveJhr0uPNL9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Operating cash flows used in operating leases</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1</td><td style="width: 1%; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20260331_zAC7ExOUUQn2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20251231_zO2zcnmg6N9b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Weighted-average remaining lease term – operating leases (in years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average remaining lease term – finance leases (in years)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260331_zU6nOxROt2dl" style="text-align: right" title="Weighted-average remaining lease term - finance leases (in years)">1.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_zDZOj8AaNRs9" style="text-align: right" title="Weighted-average remaining lease term - finance leases (in years)">2.1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average discount rate – operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">N/A</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">N/A</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zr1mwgiH6TA3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average discount rate – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.43</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.43</td><td style="text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--FinanceLeaseRightOfUseAsset_iI_pn3n3_zQUwsJkPiOgk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finance lease asset (1)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,660</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,977</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">(1)</td><td style="width: 5pt"></td><td style="text-align: justify">As of March 31, 2026 and December 31, 2025, the Company had recorded accumulated depreciation of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFF1YW50aXRhdGl2ZSBJbmZvcm1hdGlvbiBhYm91dCBPcGVyYXRpbmcgYW5kIEZpbmFuY2UgTGVhc2VzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--FinanceLeaseRightOfUseAssetAccumulatedAmortization_iI_pn5n6_c20260331_zQfaiUmsaCwe" title="Accumulated depreciation on finance lease asset">3.4 million and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFF1YW50aXRhdGl2ZSBJbmZvcm1hdGlvbiBhYm91dCBPcGVyYXRpbmcgYW5kIEZpbmFuY2UgTGVhc2VzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--FinanceLeaseRightOfUseAssetAccumulatedAmortization_iI_pn5n6_c20251231_z4vQfznkgCtc" title="Accumulated depreciation on finance lease asset">3.1 million for the finance lease asset, respectively. Finance lease assets are recorded within property and equipment, net on the Company’s Condensed Consolidated Balance Sheets.</td> </tr></table> Maturities of the Company’s remaining finance lease are as follows (in thousands): Schedule of Maturities of Finance Leases <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20260331_z692ah85Mdd2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance Lease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maFLLPDzzUM_zKba92WMeNO3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Remaining periods in 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,774</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maFLLPDzzUM_zpjPfCUe5Ovg" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Year Ended December 31, 2027</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">824</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_pn3n3_mtFLLPDzzUM_mtFLLUEzT88_zFG3CEDH7ku7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,598</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_msFLLUEzT88_zIWccUWHbMZi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Less present value discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(96</td><td style="padding-bottom: 1pt; text-align: left">) </td></tr> <tr id="xdx_40B_eus-gaap--FinanceLeaseLiability_iI_pn3n3_maFLLUEzT88_zbKPnIihuAE3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,502</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

4000

P36M

5500

170000

740000 7

4516

P5Y

1500000

0.080

P4Y

5100000

0.074

3500000

2800000

1700000

2000000.0

The following summarizes quantitative information about our operating leases (amounts in thousands): Schedule of Quantitative Information about Operating and Finance Leases <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20260101__20260331_z1CPC75r4oQe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_497_20250101__20250331_zOuKodVB5IOc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Operating leases:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr id="xdx_403_eus-gaap--OperatingLeaseCost_pn3n3_maOLEzgix_zfwKlVV7pkp1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Operating lease expense</td><td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">239</td><td style="width: 1%; text-align: left"> </td> </tr> <tr id="xdx_405_eus-gaap--OperatingLeaseExpense_iT_pn3n3_mtOLEzgix_zK7I2igWkYK8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Total operating lease expense</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">239</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Finance leases:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr id="xdx_403_eus-gaap--FinanceLeaseInterestExpense_pn3n3_maFLCztAr_zygLpX3svDyh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Interest lease cost</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">38</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">83</td><td style="text-align: left"> </td> </tr> <tr id="xdx_407_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_pn3n3_maFLCztAr_zbOxuUDgJJ15" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Depreciation expense</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">317</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">392</td><td style="text-align: left"> </td> </tr> <tr id="xdx_406_ecustom--FinanceLeaseCost_iT_pn3n3_mtFLCztAr_zVn3If8yR2G6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Total finance lease expense</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">355</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">475</td><td style="text-align: left"> </td> </tr> </table> Other information related to the Company’s leases is shown below (dollar amounts in thousands): <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_492_20260101__20260331_zrB8fDH0tWH7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20250101__20250331_z7ciSUFFhmk5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingLeasePayments_iN_pn3n3_di_zveJhr0uPNL9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Operating cash flows used in operating leases</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1</td><td style="width: 1%; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20260331_zAC7ExOUUQn2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20251231_zO2zcnmg6N9b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Weighted-average remaining lease term – operating leases (in years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average remaining lease term – finance leases (in years)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260331_zU6nOxROt2dl" style="text-align: right" title="Weighted-average remaining lease term - finance leases (in years)">1.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_zDZOj8AaNRs9" style="text-align: right" title="Weighted-average remaining lease term - finance leases (in years)">2.1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average discount rate – operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">N/A</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">N/A</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zr1mwgiH6TA3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average discount rate – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.43</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.43</td><td style="text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--FinanceLeaseRightOfUseAsset_iI_pn3n3_zQUwsJkPiOgk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finance lease asset (1)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,660</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,977</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">(1)</td><td style="width: 5pt"></td><td style="text-align: justify">As of March 31, 2026 and December 31, 2025, the Company had recorded accumulated depreciation of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFF1YW50aXRhdGl2ZSBJbmZvcm1hdGlvbiBhYm91dCBPcGVyYXRpbmcgYW5kIEZpbmFuY2UgTGVhc2VzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--FinanceLeaseRightOfUseAssetAccumulatedAmortization_iI_pn5n6_c20260331_zQfaiUmsaCwe" title="Accumulated depreciation on finance lease asset">3.4 million and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFF1YW50aXRhdGl2ZSBJbmZvcm1hdGlvbiBhYm91dCBPcGVyYXRpbmcgYW5kIEZpbmFuY2UgTGVhc2VzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--FinanceLeaseRightOfUseAssetAccumulatedAmortization_iI_pn5n6_c20251231_z4vQfznkgCtc" title="Accumulated depreciation on finance lease asset">3.1 million for the finance lease asset, respectively. Finance lease assets are recorded within property and equipment, net on the Company’s Condensed Consolidated Balance Sheets.</td> </tr></table>

239000

38000

83000

317000

392000

355000 475000

1000

P1Y9M18D

P2Y1M6D

0.0743

1660000

1977000

3400000

3100000

Maturities of the Company’s remaining finance lease are as follows (in thousands): Schedule of Maturities of Finance Leases <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20260331_z692ah85Mdd2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance Lease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maFLLPDzzUM_zKba92WMeNO3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Remaining periods in 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,774</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maFLLPDzzUM_zpjPfCUe5Ovg" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Year Ended December 31, 2027</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">824</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_pn3n3_mtFLLPDzzUM_mtFLLUEzT88_zFG3CEDH7ku7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,598</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_msFLLUEzT88_zIWccUWHbMZi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Less present value discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(96</td><td style="padding-bottom: 1pt; text-align: left">) </td></tr> <tr id="xdx_40B_eus-gaap--FinanceLeaseLiability_iI_pn3n3_maFLLUEzT88_zbKPnIihuAE3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,502</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2774000

824000

3598000

96000

3502000

Note 10 - Segment Information The Company has identified two operating segments, diagnostic services and consumer products, based on the manner in which the Company’s CEO, as Chief Operating Decision Maker, assesses performance and allocates resources across the organization. The operating segments are organized in a manner that depicts the difference in revenue generating synergies that include the separate processes, profit generation and growth of each segment. The diagnostic services segment provides diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. The unallocated corporate expenses mainly included professional fees associated with the public company. ProPhase Labs, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (unaudited) The following table is a summary of segment information for three months ended March 31, 2026 and 2025 (amounts in thousands): Schedule of Segment Information <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20260101__20260331_znEnhRn5m2qi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250101__20250331_zhwSQJDqF9Ia" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Net revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesSegmentMember_zmgStMUXzyyk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Diagnostic services</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsSegmentMember_zmCCrJIbFPtc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 60%; text-align: left; padding-bottom: 1pt">Consumer products</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">478</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">1,431</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zU5F0vZV7m95" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Consolidated net revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">478</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,431</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Cost of revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CostOfGoodsAndServicesSold_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesSegmentMember_zWc8ZHbh7Me4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Diagnostic services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">232</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--CostOfGoodsAndServicesSold_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsSegmentMember_zNuqt0tmaYqk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Consumer products</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">311</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">673</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CostOfGoodsAndServicesSold_pn3n3_zoShHS8Kf1D1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Consolidated cost of revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">311</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">905</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DepreciationAndAmortization_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesSegmentMember_z3m9Jc48P4y2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Diagnostic services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">334</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DepreciationAndAmortization_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsSegmentMember_zwvBF9C1nUXh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Consumer products</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">623</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">807</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DepreciationAndAmortization_pn3n3_zB7jZh7oHAIk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Total Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">623</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,141</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Operating and other expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--SegmentReportingOtherItemAmount_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesSegmentMember_ztuAT35h2y91" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Diagnostic services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">168</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--SegmentReportingOtherItemAmount_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsSegmentMember_zoBIxs4BwOv5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Consumer products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">562</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,061</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--SegmentReportingOtherItemAmount_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--UnallocatedCorporateMember_znfb8k9f57dd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Unallocated corporate</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,962</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,834</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--SegmentReportingOtherItemAmount_pn3n3_zccUVmzQdLhl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Total operating and other expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,524</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,063</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Income (loss) from operations, before income taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesSegmentMember_zu1sCr3n7XLk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Diagnostic services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(734</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsSegmentMember_zI25h6HZAUac" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Consumer products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,018</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,110</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--UnallocatedCorporateMember_zSsizw5B4fu8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Unallocated corporate</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,962</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,834</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_z8yaLHWaQ2z4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Total loss from operations, before income taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,980</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,678</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_iN_pn3n3_di_zkRGNBMqjBDg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Income tax expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,374</td><td style="padding-bottom: 1pt; text-align: left">) </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_pn3n3_zj7lkt8ACsta" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total loss from operations, after income taxes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,354</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,678</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_z7hjBRfwP68d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss from continuing operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,354</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,678</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> The following table is a summary of segment information as of March 31, 2026 and December 31, 2025 (amounts in thousands): <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260331_zPergIxsw4q4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20251231_zUtMM0zt6cM7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; width: 60%">ASSETS</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 16%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 16%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr id="xdx_405_eus-gaap--Assets_iI_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsSegmentMember_zVI6AX3EYEU7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Consumer products</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">10,973</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11,614</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Assets_iI_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--UnallocatedCorporateMember_zgEFKdoP6jn8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Unallocated corporate</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">47,757</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">48,257</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperation_iI_pn3n3_zqAvpOxjj2Z9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">58,730</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">59,871</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

The following table is a summary of segment information for three months ended March 31, 2026 and 2025 (amounts in thousands): Schedule of Segment Information <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20260101__20260331_znEnhRn5m2qi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250101__20250331_zhwSQJDqF9Ia" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Net revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesSegmentMember_zmgStMUXzyyk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Diagnostic services</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsSegmentMember_zmCCrJIbFPtc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 60%; text-align: left; padding-bottom: 1pt">Consumer products</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">478</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">1,431</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zU5F0vZV7m95" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Consolidated net revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">478</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,431</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Cost of revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CostOfGoodsAndServicesSold_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesSegmentMember_zWc8ZHbh7Me4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Diagnostic services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">232</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--CostOfGoodsAndServicesSold_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsSegmentMember_zNuqt0tmaYqk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Consumer products</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">311</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">673</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CostOfGoodsAndServicesSold_pn3n3_zoShHS8Kf1D1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Consolidated cost of revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">311</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">905</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DepreciationAndAmortization_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesSegmentMember_z3m9Jc48P4y2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Diagnostic services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">334</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DepreciationAndAmortization_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsSegmentMember_zwvBF9C1nUXh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Consumer products</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">623</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">807</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DepreciationAndAmortization_pn3n3_zB7jZh7oHAIk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Total Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">623</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,141</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Operating and other expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--SegmentReportingOtherItemAmount_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesSegmentMember_ztuAT35h2y91" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Diagnostic services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">168</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--SegmentReportingOtherItemAmount_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsSegmentMember_zoBIxs4BwOv5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Consumer products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">562</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,061</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--SegmentReportingOtherItemAmount_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--UnallocatedCorporateMember_znfb8k9f57dd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Unallocated corporate</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,962</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,834</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--SegmentReportingOtherItemAmount_pn3n3_zccUVmzQdLhl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Total operating and other expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,524</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,063</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Income (loss) from operations, before income taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--DiagnosticServicesSegmentMember_zu1sCr3n7XLk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Diagnostic services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(734</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsSegmentMember_zI25h6HZAUac" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Consumer products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,018</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,110</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--UnallocatedCorporateMember_zSsizw5B4fu8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Unallocated corporate</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,962</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,834</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_z8yaLHWaQ2z4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Total loss from operations, before income taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,980</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,678</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_iN_pn3n3_di_zkRGNBMqjBDg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Income tax expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,374</td><td style="padding-bottom: 1pt; text-align: left">) </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_pn3n3_zj7lkt8ACsta" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total loss from operations, after income taxes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,354</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,678</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_z7hjBRfwP68d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss from continuing operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,354</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,678</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> The following table is a summary of segment information as of March 31, 2026 and December 31, 2025 (amounts in thousands): <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260331_zPergIxsw4q4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20251231_zUtMM0zt6cM7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; width: 60%">ASSETS</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 16%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 16%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr id="xdx_405_eus-gaap--Assets_iI_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ConsumerProductsSegmentMember_zVI6AX3EYEU7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Consumer products</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">10,973</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11,614</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Assets_iI_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--UnallocatedCorporateMember_zgEFKdoP6jn8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Unallocated corporate</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">47,757</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">48,257</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperation_iI_pn3n3_zqAvpOxjj2Z9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">58,730</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">59,871</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

478000

1431000

478000

1431000

232000

311000

673000

311000

905000

334000

623000

807000

623000

1141000

168000

562000

1061000

2962000

2834000

3524000

4063000

-734000

-1018000

-1110000

-2962000

-2834000

-3980000

-4678000

1374000

-5354000

-4678000

-5354000

-4678000

10973000

11614000

47757000

48257000

58730000

59871000

Note 11 - Net Earnings (Loss) Per Share Basic earnings (loss) per share excludes dilution and is computed by dividing income available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or otherwise result in the issuance of common stock that shared in the earnings of the entity. Diluted earnings (loss) per share also utilizes the treasury stock method which prescribes a theoretical buy back of shares from the theoretical proceeds of all options outstanding during the period, and the if-converted method for convertible debt. The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share (in thousands): Schedule of Reconciliation of the Weighted Average Number of Common Shares Outstanding used in Calculating Basic and Diluted Net Loss Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260101__20260331_zu69BeKbpZP9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250101__20250331_ziN4LdKjE8li" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_maNILz6pO_z5dz1vgm3xZb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Loss from continuing operations after income taxes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(5,354</td><td style="width: 1%; text-align: left">) </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(4,678</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_pn3n3_maNILz6pO_zEFcIgpXFX9k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Income from discontinued operations, net of tax</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">8,644</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--NetIncomeLoss_iT_pn3n3_mtNILz6pO_zPEWVdg47rV1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net (loss) income</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,354</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,966</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB_pn3n3_zJtIWaHTtRs" style="vertical-align: bottom; background-color: White"> <td>Weighted average common shares outstanding:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pn3n3_z6urMCKKN6Ef" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Basic</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,317</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,523</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_pn3n3_zoyQWiwMEfPe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,317</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,523</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareBasicAbstract_iB_zj8uBwkOgvqa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Net earnings (loss) per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Loss from continuing operations, basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.43</td><td style="padding-bottom: 2.5pt; text-align: left">) </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.33</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Income from discontinued operations, basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2.45</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss (earnings) per share, basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.43</td><td style="padding-bottom: 2.5pt; text-align: left">) </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> ProPhase Labs, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (unaudited) <p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zaCVQCoHl54i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table represents the number of securities excluded from the income per share computation as a result of their anti-dilutive effect (in thousands): Schedule of Anti-dilutive Securities Excluded from the Income Per Share Computation <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Anti-dilutive securities</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260101__20260331_znMfj7jYxZYd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20250101__20250331_zDxtoVifxS02" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Anti-dilutive securities</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockPurchaseWarrantsMember_zX4ndZDl0971" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Common stock purchase warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">997</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">74</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zlRzKoGLqQlj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">478</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">472</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zrDi0gLxCTOk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Convertible notes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,981</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_zJ8Rsc62Defk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Anti-dilutive securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,456</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">546</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share (in thousands): Schedule of Reconciliation of the Weighted Average Number of Common Shares Outstanding used in Calculating Basic and Diluted Net Loss Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260101__20260331_zu69BeKbpZP9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250101__20250331_ziN4LdKjE8li" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_maNILz6pO_z5dz1vgm3xZb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Loss from continuing operations after income taxes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(5,354</td><td style="width: 1%; text-align: left">) </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(4,678</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_pn3n3_maNILz6pO_zEFcIgpXFX9k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Income from discontinued operations, net of tax</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">8,644</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--NetIncomeLoss_iT_pn3n3_mtNILz6pO_zPEWVdg47rV1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net (loss) income</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,354</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,966</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB_pn3n3_zJtIWaHTtRs" style="vertical-align: bottom; background-color: White"> <td>Weighted average common shares outstanding:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pn3n3_z6urMCKKN6Ef" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Basic</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,317</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,523</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_pn3n3_zoyQWiwMEfPe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,317</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,523</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareBasicAbstract_iB_zj8uBwkOgvqa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Net earnings (loss) per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Loss from continuing operations, basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.43</td><td style="padding-bottom: 2.5pt; text-align: left">) </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.33</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Income from discontinued operations, basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2.45</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss (earnings) per share, basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.43</td><td style="padding-bottom: 2.5pt; text-align: left">) </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

-5354000

-4678000

8644000

-5354000

3966000

12317000

3523000

12317000

3523000

-1.33

2.45

1.13

<p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zaCVQCoHl54i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table represents the number of securities excluded from the income per share computation as a result of their anti-dilutive effect (in thousands): Schedule of Anti-dilutive Securities Excluded from the Income Per Share Computation <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Anti-dilutive securities</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260101__20260331_znMfj7jYxZYd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20250101__20250331_zDxtoVifxS02" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Anti-dilutive securities</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockPurchaseWarrantsMember_zX4ndZDl0971" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Common stock purchase warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">997</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">74</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zlRzKoGLqQlj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">478</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">472</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zrDi0gLxCTOk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Convertible notes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,981</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_zJ8Rsc62Defk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Anti-dilutive securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,456</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">546</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

997000

74000

478000

472000

10981000

12456000

546000

Note 12 - Related Parties The Company’s President of Nebula Genomics, Inc., is a related party to the Company’s Chairman and Chief Executive Officer. For the three months ended March 31, 2026 and 2025, there were no payments made to the Executive Vice President outside compensation and benefits for the position held at the Company. On February 18, 2025, the company announced that Stuart Hollenshead was appointed to serve as Chief Operating Officer of the Company, effective on February 17, 2025. Mr. Hollenshead resigned his COO position effective July 31, 2025 and resumed his prior role with the Company in the role as a marketing consultant. Mr. Hollenshead serves as CEO of 10PM Curfew. The Company received consulting services from 10PM Curfew on an ongoing basis. For the three months ended March 31, 2026 and 2024, the Company did <span id="xdx_901_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_do_c20250101__20250331__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember__us-gaap--RelatedPartyTransactionAxis__custom--ConsultingServicesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zy81jbGloIea">not incurred any consulting services from 10pm Curfew. For the nine months ended September 30, 2025 and 2024, consulting services from 10PM Curfew totaled approximately $<span id="xdx_900_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20250101__20250930__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember__us-gaap--RelatedPartyTransactionAxis__custom--ConsultingServicesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zRmlq60LwO0b" title="Related party transaction amounts">167,000 and <span id="xdx_901_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20240101__20240930__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember__us-gaap--RelatedPartyTransactionAxis__custom--ConsultingServicesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVy4jQQLgPBb" title="Related party transaction amounts">165,000one hundred sixty-five thousand, respectively. Amounts payable 10PM Curfew as of March 31, 2026 was <span id="xdx_906_eus-gaap--AccountsPayableCurrent_iI_dc_c20260331__srt--TitleOfIndividualAxis__custom--FormerChiefOperatingOfficerMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zDMq2MeIHsnd" title="Accounts payable, current">zero. The Company continues to utilize 10PM Curfew for consulting services. On June 22, 2025, the Company entered into a loan agreement with Ted Karkus, the Company’s Chief Executive Officer and the Chairman of the Board of Directors, pursuant to which the Company issued a twelve-month non-convertible promissory note in the principal amount of $625,000. The Company also issued <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250622__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zkCJiLea2pTd" title="Number of warrants or rights outstanding">500,000 unvested warrants in conjunction with the note agreement. See Note 6 for detail description regarding the CEO Loan and the CEO Warrants.

167000

165000

625000

500000

Note 13 - Discontinued Operations On January 16, 2025, the Company entered into a Stock Purchase Agreement (the “Agreement”) with JL Projects, Inc., a Delaware corporation (“JL Projects”), pursuant to which JL Projects purchased from the Company all of the right, title, and interest in and to all of the issued and outstanding shares of capital stock of Pharmaloz Manufacturing, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (“PMI”), and Pharmaloz Real Estate Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (“PREH”). The transaction closed concurrently with the execution of the Agreement on January 16, 2025. As part of the transaction, JL Projects provided approximately $<span id="xdx_90B_eus-gaap--ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_pn6n6_c20250116__20250116__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zBG00NC2ULNe">2 million in cash payments to the Company and extinguished approximately $<span id="xdx_90B_eus-gaap--NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_pn6n6_c20250116__20250116__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zTdoRl50XHna">10 million of the Company’s debt. Additionally, JL Projects assumed (i) the existing $<span id="xdx_908_eus-gaap--NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_pn5n6_c20250116__20250116__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember__us-gaap--NoncashOrPartNoncashDivestituresByUniqueNameAxis__custom--PMINoteMember_z7bHYSdyCXb2">3.3 million mortgage on PMI’s manufacturing facility, (ii) nearly $<span id="xdx_904_eus-gaap--NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_pn6n6_c20250116__20250116__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember__us-gaap--NoncashOrPartNoncashDivestituresByUniqueNameAxis__custom--CapitalLeasesMember_z3dB2nE6GqZ8">2 million in capital leases, and (iii) approximately $<span id="xdx_90E_eus-gaap--NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_pn6n6_c20250116__20250116__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember__us-gaap--NoncashOrPartNoncashDivestituresByUniqueNameAxis__custom--CurrentAndAccruedPayablesMember_z9cD65l5Juqf">3 million in current and accrued payables, and paid down $<span id="xdx_905_eus-gaap--NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_pp0p0_c20250116__20250116__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember__us-gaap--NoncashOrPartNoncashDivestituresByUniqueNameAxis__custom--ExistingLoanFromAffiliatesMember_zW2Vjl4nbxSi">200,000 on an existing loan from affiliates of JL Projects. The transaction also resulted in the cancellation of approximately $<span id="xdx_90A_eus-gaap--NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_pp0p0_c20250116__20250116__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember__us-gaap--NoncashOrPartNoncashDivestituresByUniqueNameAxis__custom--AccruedInterestMember_zTTOFLHOuiG">300,000 in accrued interest related to the retired debt. Furthermore, the Company avoided approximately $<span id="xdx_901_ecustom--NoncashOrPartNoncashDivestitureCapitalExpendituresAvoided_pn6n6_c20250116__20250116__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zy65uRQ1V4eb" title="Non cash or part non cash divestiture capital expenditures avoided">3 million of upcoming capital expenditures that JL Projects will now be responsible for. The transaction also transferred over $<span id="xdx_901_ecustom--NoncashOrPartNoncashDivestitureEmployeeAnnualOverheadTransferred_pp0p0_c20250116__20250116__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zsgCi83KK9og" title="Employee annual overhead">600,000 in employee annual overhead from the Company to PMI. As a result, the Company recognized a gain on sale of PMI and PREH of approximately $<span id="xdx_90A_eus-gaap--DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_pn5n6_c20250101__20250331__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_z5syI8hNFzVl">8.7 million for the three months ended March 31, 2025. The Company has reported the results of the discontinued operations as a separate component of income below the income (loss) from continuing operations in each period presented.

2000000

10000000

3300000

2000000

3000000

200000

300000

3000000 600000

8700000

Note 14 - Voluntary Bankruptcy Filing and Deconsolidation On September 22, 2025 (the “Petition Date”), the Company’s wholly-owned subsidiary, ProPhase Diagnostics, Inc., and two indirectly wholly-owned subsidiaries, ProPhase Diagnostics NY, Inc. and ProPhase Diagnostics NJ, Inc. (collectively the “PDX”) filed for a Chapter 11 reorganization in United States Bankruptcy Court for the District of New Jersey (the “Chapter 11 case”). On September 30, 2025, the Court granted the motion for joint administration. During the Chapter 11 Case, the Company is deemed to no longer control PDX as its activities are subject to review and oversight by the Bankruptcy Court. Therefore, PDX was deconsolidated from the Company’s condensed consolidated financial statements prospectively as of September 22, 2025. Deconsolidation of Bankrupt Subsidiaries In order to deconsolidate PDX, the carrying values of the assets and liabilities of PDX were removed from the Company’s condensed consolidated balance sheet as of September 22, 2025, in accordance with ASC 810, Consolidation. The net impact with removing the assets and liabilities held at PDX resulted in the recognition of the investment in unconsolidated affiliates of $43.7 million, and a payable to unconsolidated affiliates of $<span id="xdx_90A_eus-gaap--AccountsPayableCurrent_iI_pn5n6_c20250930__srt--CounterpartyNameAxis__custom--PDXMember__us-gaap--RelatedPartyTransactionAxis__srt--AffiliatedEntityMember_zNJqoqqhfPia" title="Accounts payable">27.7 million on the Company’s condensed consolidated balance sheet as of September 30, 2025. Subsequent to the deconsolidation, the Company will account for the equity interest in PDX under the equity method of accounting as the Company is deemed to still have significant influence over PDX. For the three months ended March 31, 2026, the Company recognized approximately $225,000 loss from investment in PDX. ProPhase Labs, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (unaudited) All post-deconsolidation activities between the Company and PDX are reported as third-party transactions recorded within the Company’s Unaudited Condensed Consolidated Statement of Operations. Since the Petition Date, there were no material transactions between the Company and PDX. Treatment of Intercompany Balances The Company had total payables to PDX of approximately $27.6 million and $27.7 million as of March 31, 2026 and December 31, 2025, respectively.

43700000

27700000

225000

27600000

27700000

Note 15 - Fair Value Measurements The following table presents the fair value of the Company’s financial liabilities that are measured at fair value on a recurring basis as of March 31, 2026 and December 31, 2025 (in thousands): Schedule of Fair Value of the Company’s Financial Liabilities That are Measured at Fair Value On a Recurring Basis <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 85%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z2Z6h6aOkP82" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zn3b5CkMjOv8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxm91YMkx8Tb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z9UTYxInRgU9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_ecustom--WarrantLiabilityFairValueDisclosure_iI_pn3n3_zsih42IIsel8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left; width: 44%">Derivative liability</td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; width: 1%">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; width: 10%">-</td><td style="padding-bottom: 2.5pt; text-align: left; width: 1%"> </td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; width: 1%">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; width: 10%">-</td><td style="padding-bottom: 2.5pt; text-align: left; width: 1%"> </td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; width: 1%">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; width: 10%">490</td><td style="padding-bottom: 2.5pt; text-align: left; width: 1%"> </td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; width: 1%">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; width: 10%">490</td><td style="padding-bottom: 2.5pt; text-align: left; width: 1%"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 85%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zQPsr6Uzy2Ba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxHYHDGQH4xi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTNUL2AT16ll" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zF2376ulfUE2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_ecustom--WarrantLiabilityFairValueDisclosure_iI_pn3n3_zgJIdxHkchP3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left; padding-bottom: 2.5pt">Derivative liability</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">-</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">-</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">50</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">50</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> There were no transfers between Level 1, 2 or 3 during the three-month period ended March 31, 2026. The following table presents changes in Level 3 liabilities measured at fair value for the three-month period ended March 31, 2026. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs (in thousands). <p id="xdx_89F_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_znKeJ7Z97Nfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> Schedule of Changes in Fair Value <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-right: auto; margin-left: auto; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20250101__20250930__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeMember_zjo5iKUWrzXh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Derivative liability</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_z4BoTdYvJDwh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Balance at January 1, 2026</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 18%">50</td><td style="text-align: left; width: 1%"> </td></tr> <tr id="xdx_40B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_pn3n3_hus-gaap--DebtInstrumentAxis__custom--JulyTwoThousandTwentyFiveNotesMember_zQmoxIxFmuIi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Issuance of convertible debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">308</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_pn3n3_zDPdvBd3S2ed" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Debt amendment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">418</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_iN_pn3n3_di_hus-gaap--DebtInstrumentAxis__custom--AugustFutureFinancingAgreementMember_zqi4dSn0Kfi9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Redemptions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(372</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_pn3n3_zSkJSnJzD5ci" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">86</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_zUyyt44CTLRd" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">490</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in the Black-Scholes option pricing model and Monte-Carlo simulation measuring the Company’s derivative liabilities that are categorized within Level 3 of the fair value hierarchy as of March 31, 2026 and December 31, 2025: <p id="xdx_898_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zfHFwhWm6XA5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> Schedule of Fair Value Measurement Inputs and Valuation Techniques <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20250909_zbbmcGey0CQb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20250930_z55yLtC1kfdl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zar6y4k6H9f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Exercise price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.07</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.76</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.6</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zZmuyKr3J7fg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">154.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">99.2</td><td style="text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zDlzq53zUDs9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate of interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.7</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.6</td><td style="text-align: left">%</td></tr> <tr id="xdx_40C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zWgVLAULzYFe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expected dividend yield (per share)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zK4ePTPfccw7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrants outstanding measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> </table>

The following table presents the fair value of the Company’s financial liabilities that are measured at fair value on a recurring basis as of March 31, 2026 and December 31, 2025 (in thousands): Schedule of Fair Value of the Company’s Financial Liabilities That are Measured at Fair Value On a Recurring Basis <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 85%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z2Z6h6aOkP82" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zn3b5CkMjOv8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxm91YMkx8Tb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z9UTYxInRgU9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_ecustom--WarrantLiabilityFairValueDisclosure_iI_pn3n3_zsih42IIsel8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left; width: 44%">Derivative liability</td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; width: 1%">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; width: 10%">-</td><td style="padding-bottom: 2.5pt; text-align: left; width: 1%"> </td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; width: 1%">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; width: 10%">-</td><td style="padding-bottom: 2.5pt; text-align: left; width: 1%"> </td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; width: 1%">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; width: 10%">490</td><td style="padding-bottom: 2.5pt; text-align: left; width: 1%"> </td><td style="padding-bottom: 2.5pt; width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; width: 1%">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; width: 10%">490</td><td style="padding-bottom: 2.5pt; text-align: left; width: 1%"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 85%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zQPsr6Uzy2Ba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxHYHDGQH4xi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTNUL2AT16ll" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zF2376ulfUE2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_ecustom--WarrantLiabilityFairValueDisclosure_iI_pn3n3_zgJIdxHkchP3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left; padding-bottom: 2.5pt">Derivative liability</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">-</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">-</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">50</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">50</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

490000 490000 50000 50000

<p id="xdx_89F_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_znKeJ7Z97Nfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> Schedule of Changes in Fair Value <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-right: auto; margin-left: auto; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20250101__20250930__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeMember_zjo5iKUWrzXh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Derivative liability</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_z4BoTdYvJDwh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Balance at January 1, 2026</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 18%">50</td><td style="text-align: left; width: 1%"> </td></tr> <tr id="xdx_40B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_pn3n3_hus-gaap--DebtInstrumentAxis__custom--JulyTwoThousandTwentyFiveNotesMember_zQmoxIxFmuIi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Issuance of convertible debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">308</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_pn3n3_zDPdvBd3S2ed" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Debt amendment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">418</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_iN_pn3n3_di_hus-gaap--DebtInstrumentAxis__custom--AugustFutureFinancingAgreementMember_zqi4dSn0Kfi9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Redemptions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(372</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_pn3n3_zSkJSnJzD5ci" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">86</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_zUyyt44CTLRd" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">490</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

50000

308000

418000

372000

86000

490000

<p id="xdx_898_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zfHFwhWm6XA5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> Schedule of Fair Value Measurement Inputs and Valuation Techniques <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20250909_zbbmcGey0CQb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20250930_z55yLtC1kfdl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zar6y4k6H9f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Exercise price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.07</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.76</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.6</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zZmuyKr3J7fg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">154.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">99.2</td><td style="text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zDlzq53zUDs9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate of interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.7</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.6</td><td style="text-align: left">%</td></tr> <tr id="xdx_40C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zWgVLAULzYFe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expected dividend yield (per share)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zK4ePTPfccw7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrants outstanding measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> </table>

0.07

0.76

P0Y7M6D

154.5

99.2

3.7

3.6

Note 16 - Subsequent Events On June 4, 2026, the Company’s wholly-owned subsidiary, DNA Complete, Inc. (“DNA Complete”), entered into an agreement of sale of future receipts (the “Third 2026 Future Receipts Financing Agreement”) with Legendary Funding Group, LLC (“Legendary”), by which Legendary purchased from DNA Complete its future accounts and contract rights arising from the sale of goods or rendition of services to DNA Complete’s customers, equal to a specified percentage of future receipts. The purchase price was $60,000, which was paid to DNA Complete net of a $6,000 origination fee, resulting in net proceeds of $<span id="xdx_908_eus-gaap--BusinessCombinationConsiderationTransferred1_c20260604__20260604__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zU6Bh5SyOzP6" title="Business combination transferred">54,000.

60000

6000

54000

false false false false Net of 600,000 collateral shares. See Note 5. As of March 31, 2026 and December 31, 2025, the Company had recorded accumulated depreciation of approximately $3.4 million and $3.1 million for the finance lease asset, respectively. Finance lease assets are recorded within property and equipment, net on the Company’s Condensed Consolidated Balance Sheets.